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Abstract 
 
Cancer is a devastating disease worldwide, with millions of diagnoses per year and many 
people living with this pathology. Breast cancer is one of the major causes of death in women 
while male breast cancer represents less than 1% of the total male diagnosed population. Due 
to this increasing cancer incidence, research in this area has been growing at the same rate. 
Thus, there is an urgency in discovering new drugs for cancer treatment. 
The chromene scaffold has been identified in several compounds with anticancer 
activity. The substitution pattern highly influences the activity and the mode of action and the 
synthesis of new derivatives is an important element in the search for improved drug candidates. 
The major aim of this Master thesis was the synthesis of new chromene derivatives with 
enhanced anticancer activity. 
Chalcone and chromene derivatives were isolated in good yield through clean reactions 
using innocuous solvents such as water and ethanol and highly effective aldol condensations. 
Generally, the reactions were performed at room temperature, leading to the isolation of highly 
pure compounds. 
Newly synthetized compounds were tested on cancer cells and a non-tumoral cell line. 
For the first screening, a range of 51 compounds was assessed for cell survival by SRB assay on 
MCF-7 cells. Then, only the 22 most active compounds were tested against another breast 
cancer cell line (HS578t) and cytotoxicity was evaluated for MCF-10 normal cells. Then, a 
selection of the eight most promising chalcones and chromenes had their IC50 determined for all 
three cell lines. Finally, some more specific assays were performed and it was found that a 
selected chromene acted as a cell migration inhibitory agent. Some preliminary results, with 
protein expression, also showed that this chromene might be causing its anticancer activity 
through induction of cell-apoptosis. For chalcones, the results suggest an anti-proliferative 
ability and reduction of membrane integrity. 
Generally, compounds with halogenated substituents presented enhanced activity 
comparing to methoxy or methyl groups. More specifically, the bromine atom was often present 
in the bioactive molecules that proceeded to the final assays and showed to be promising 
candidates for further studies.  
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Resumo 
 
O cancro é uma doença devastadora que em todo o mundo apresenta milhões de 
diagnósticos por ano e muitas pessoas vivem com esta patologia. O cancro da mama é uma das 
maiores causas de morte entre a população feminina enquanto que, o cancro da mama 
masculino afeta menos de 1% de todos os diagnósticos oncológicos nos homens. Devido à 
crescente incidência de cancro, a investigação farmacológica nesta área tem vindo a crescer na 
mesma proporção. Assim, a descoberta de novas drogas para tratamento oncológico representa 
uma urgência. 
O núcleo de cromeno foi identificado em diversos compostos com atividade 
anticancerígena. O padrão de substituição demonstra afetar a atividade e o modo de ação e a 
síntese de novos derivados é um elemento importante em investigação para melhorar a ação 
do candidato. O principal objetivo desta tese de Mestrado era sintetizar novos derivados de 
cromeno com atividade anticancerígena melhorada. 
Vários derivados de calconas e cromenos foram isolados com bons rendimentos, através 
de reações limpas usando solventes inócuos tais como água e etanol, em condensações aldólicas 
altamente efetivas. Na generalidade, as reações foram realizadas à temperatura ambiente, 
levando ao isolamento de compostos altamente puros. 
Os recém-sintetizados compostos foram testados em linhas celulares de cancro e numa 
linha celular não-tumoral. Num primeiro screening, um lote de 51 compostos foi testado para a 
viabilidade celular por ensaio com sulforodamina em células MCF-7. Então, apenas os 22 
compostos mais ativos foram testados para outra linha celular (HS578t) e a citotoxicidade foi 
avaliada em células normais MCF-10. Uma série dos oito compostos mais promissores para as 
três linhas celulares, foi selecionada e teve o IC50 determinado. Finalmente, alguns ensaios mais 
específicos foram elaborados e registou-se que o único cromeno selecionado apresentou poder 
para inibição da migração celular. Alguns resultados preliminares, para expressão proteica, 
clarificaram que este cromeno poderá estar a agir como agente anticancerígeno através da 
indução da apoptose. Para as calconas testadas, os resultados sugerem uma capacidade 
antiproliferativa e a redução da integridade membranar. 
Em geral, os compostos com substituintes halogenados exibiram melhor atividade em 
comparação com grupos metilo ou metoxilo. Mais especificamente, o átomo de bromo esteve 
por diversas vezes presente nas moléculas bioativas que procederam para os ensaios finais e 
demostraram ser candidatos promissores para estudos futuros. 
 
 
PALAVRAS-CHAVE adição de Michael | anti-migratório | cancro da mama | calconas | 4H-cromenos | MCF-7 
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1. CaŶĐer 
Cancer is the name given to a group of related diseases where part of the body cells start 
to grow uncontrollably and spread into contiguous tissues [1,2]. Cancer is the second leading 
cause of death in contemporary society, preceded by cardiovascular diseases. In 2012, 
approximately 14 million people around the world were diagnosed with cancer, about 8.2 
million deaths were registered due to this disease and 32.6 million people live with cancer 
(within 5 years of diagnosis) [1,3]. 
For the first time, in 2000, Hanahan and Weinberg defined the succession of acquired 
abilities which allow cancer cells to survive, proliferate and disseminate, as hallmarks of cancer 
[2,4]. Self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of 
programmed cell death, unlimited replicative potential, sustained angiogenesis and tissue 
invasion and metastasis were the six hallmarks proposed [2].  
Recently, these hallmarks were reviewed and modified by the same authors, including 
the ability to alter or reprogram cellular metabolism and the capability of evasion to 
immunological destruction [5]. Consequently, two more consequential features were defined: 
the inflammation by innate immune cells and the genomic instability and mutation. Additionally, 
in 2012, Floor and co-workers mentioned another essential characteristic – loss of 
differentiation [6]. 
 
 
 
 
 
 
 
 
 
 
Figure 1. The Hallmarks of Cancer. Schematic illustration of the acquired capabilities of tumor cells essential 
for tumor growth and progression (adapted from [5]). 
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These hallmark abilities are acquired through deregulation of signaling pathways which, 
in combination with the interconnections and crosstalk between the individual sub-circuits, can 
lead to alteration of multiple capabilities through a certain oncogenic event [5]. 
Over the years, the knowledge about carcinogenesis has increased and two models were 
suggested to describe the development of cancer cells. The stochastic model defends that any 
type of cell is able of initiating and promoting tumor development and the cancer stem cell (CSC) 
model which suggests that tumors are hierarchically structured and cancer-promoting potential 
is only present in CSCs [7,8]. 
According to this information, cancer is a rather heterogeneous pathology related to 
defects in terms of the regulatory circuits that control cellular homeostasis, including death, 
proliferation, differentiation and cell migration and, due to this dynamic system, there is an 
explicit difficulty to reach an effective treatment to this disease [9,10]. 
 
1.1. Breast cancer 
Breast cancer is the most frequent cancer in women worldwide and the fifth cause of 
death from cancer, with 522.000 deaths in 2012. Furthermore, with an estimated 1.67 million 
new cases, it is considered the second most common cancer in the world (Figure 2) [3]. 
Moreover, successive demographic and epidemiologic transitions, predominantly in less 
developed countries, have a huge contribution in the increased incidence of cancer and, until 
2025, it is expected an occurrence of 20 million cancer cases every year [11]. On the other hand, 
male breast cancer (MBC), with less than 1% of the total cancer diagnoses in male population, 
is very uncommon [12,13]. Over the years, MBC mortality is increasing due to lack of male 
population concern about this pathology. Consequently, male patients are diagnosed in a more 
advanced stage of the disease [13,14]. 
In Portugal, for both sexes, breast cancer had an incidence and mortality of 12,4% and 
6.5%, respectively, in 2012 [3]. Due to its high incidence, breast cancer is one of the diseases 
that shows more concern by the scientific community. This fact led to an increasing search for 
new anticancer drugs with increasing potential for prevention and treatment. 
As prevention for breast cancer, a leading medical screening procedure was 
implemented: mammography. However, not all the cases of breast cancer have successful 
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endings so it is important to understand this cancer heterogeneity and improve prevention, 
diagnosis and survival for the specific subtypes [15–18]. 
 
Over the last five decades, the inter and intravariability of breast cancer tumors have 
been studied by histopathology methods [19]. Recently, new techniques like microarrays and 
next-generation sequencing, by advances in genetic sequencing and molecular analysis, were 
combined and employed to describe the multiplicity of breast tumor subtypes [20,21]. Hence, 
luminal A, luminal B, HER2-overexpressing and triple negative were the breast cancer tumor 
subtypes defined through genetic and molecular methods (Table 1) [22–24]. This classification 
was possible according to the evaluation of progesterone (PR) or estrogen receptors (ER) by 
immunohistochemistry (IHC) and fluorescent in situ hybridization. In recent years, as a form to 
differentiate aggressiveness or tumor cell proliferation in the several types of breast cancer, new 
tumor procedures for classification, such as Ki-67 status or histologic grade, were labored [22]. 
This novel established approach aims at more effective treatments in terms of surgery, 
chemotherapy, radiotherapy or new targeted therapies  [23,25,26]. 
According to the different subtypes of breast cancer, the treatment used will also be 
changed. From all the four subtypes of breast tumors, luminal A tends to have a best prognosis, 
with high rates of survival and equally low recurrence rates. Due to the presence of ER-positivity, 
treatment for these tumors generally includes a diversified hormone therapy as tamoxifen 
(Figure 3) and/or aromatase inhibitors [27,28]. 
Figure 2. Estimated incidence for all types of cancer worldwide (adapted from [3]). 
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Figure 3. Hormone therapy agent: tamoxifen. 
 
Before discovering that HER2 subtype tumors could have a target for treatment, women 
with these tumors had a very poor prognosis. However, nowadays, for tumors HER2-positive, it 
is common to treat this cancer subtype with anti-HER2 drugs such as trastuzumab [29]. 
 
 
Table 1. Molecular subtypes of breast cancer (adapted from [30]). 
Intrinsic subtypes (GEP) IHC classification (St Gallen) Agreement IHC/GEP 
Luminal A ͞LuŵiŶal A͟ 
    ER and/or PR positive 
    HER2 negative 
    Ki-67<14% 
73%-100% 
Luminal B ͞LuŵiŶal B ;HERϮ ŶegatiǀeͿ͟ 
     ER and/or PR positive 
    HER2 negative 
    Ki-ϲϳ≥ϭϰ% 
͞LuŵiŶal B ;HERϮ positiǀeͿ͟ 
    ER and/or PR positive 
    Any Ki-67 
    HER2 over-expressed or amplified 
73%-100% 
HER2-enriched ͞HERϮ positive (non-luŵiŶalͿ͟ 
    HER2 over-expressed or amplified 
    ER and PR absent 
41%-69% 
Basal-like ͞Tƌiple Ŷegatiǀe͟ 
    ER and PR absent 
    HER2 negative 
80% 
(ER, estrogen receptor; PR, progesterone receptor; GEP, gene expression profiling; HER2, human epidermal growth 
factor receptor 2) 
 
 Basal-like tumors are the most aggressive subtype of breast cancer. Because of their 
negativity for ER and HER2, hormone therapy and trastuzumab cannot be used as treatments. 
So, generally, a combination of surgery, radiotherapy and chemotherapy is used, making the 
treatment with larger scope but also more aggressive to the patients [31]. Targeted therapies 
for basal-like tumors do not exist however treatment options are currently being studied. As 
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possible targets for coming therapies, epidermal growth factor receptor and androgen receptor 
were mentioned [32].  
 
 
1.1.1. Breast cancer treatments 
Treatment for breast cancer depends on the general health of the patient as well as the 
stage and grade of cancer and may include a combination of surgery and radiation, chemical, 
immunological and targeted therapies. The typical treatment for the patients with stage I tumors 
involves surgery to remove the cancer and a small amount of tissue around the tumor 
(lumpectomy) [33]. Stage II patients are considered for adjuvant chemotherapy as a preventive 
strategy against cancer recurrence [33]. Patients with stage III disease, having a high rate of 
recurrence and cancer related death, are usually considered for adjuvant chemotherapy [28,29]. 
However, as referred previously, breast cancer is divided into four different subgroups according 
to the expression of PR, ER or both. This differential expression on the surface of cancer cells 
will condition adjuvant chemotherapy. Regarding targeted therapies, tumors with over-
expression of HER2 are treated with an anti-HER2 antibody, such as trastuzumab, or a tyrosine 
kinase inhibitor, such as lapatinib (Figure 4) [30,31]. Triple negative tumors, with absent 
expression of PR, ER and HER2 and increased rates of metastasis, relapse and death, compared 
to other breast cancer types, are treated with cytotoxic chemotherapy due to the lack of 
targeted therapies [31]. 
 
 
 
 
 
Radiotherapy treatment uses X-ray or other types of radiation to kill and inhibit the 
continuous proliferation of cancer cells [37]. Two types of radiation therapy may be performed: 
external radiation which sends radiation to the cancer from a machine outside the body and 
internal radiation, that injects radioactive substances into or near the tumor [38]. This procedure 
will vary depending on the type and stage of treating cancer [35–37]. 
Figure 4. Chemical structure of drugs used in targeted therapy: lapatinib. 
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The cancer treatment that uses drugs to stop tumor cellular growth is defined as 
chemotherapy. This procedure acts essentially in the hallmark of cancer characterized by the 
evasion from growth suppressors and its action leads to cellular division arrest (mitosis) or cell 
death (apoptosis) [42]. This type of therapy has two different ways of administration: systemic 
chemotherapy, in which the drug enters into the bloodstream and regional chemotherapy, that 
places the drug directly in the local of action [38,39]. However, as tumor cells share mechanisms 
of action with normal cells, there are many side effects that limit the patient life during the 
treatment [44]. Chemotherapy, because of its cytotoxic and non-selective properties, has 
limited clinical applications [45]. So, hematological malignancies, metastatic solid cancers and 
primary cancers as an aide to surgery, by their high proliferative index and as an attempt of 
localized treatment, are the main applications of this type of treatment [42]. 
The drugs administrated through chemotherapy are divided into classes according to 
the drug target and its mechanism of action [43]. Hence, some of the highlighted classes with 
current and common use are: 
i. Alkylating agents which damage the DNA by formation of covalent bonds, inducing 
single-strand or double-strand breaks that lead to DNA cross-linking, preventing cellular 
proliferation. Chlorambucil [46] and busulfan [47] are two examples of the many 
alkylating agents currently available (Figure 5). 
 
 
 
 
ii. Antimetabolites affect the RNA and DNA growth by the introduction of similar pyrimidine 
and purine analogues into the strand. S phase is generally affected by these drugs. As 
examples, methotrexate [48], pemetrexed [49] and 5-fluorouracil (5-FU) are represented 
in Figure 6 [48]. 
Figure 5. Chemical structures of chlorambucil and busulfan, two examples of alkylating agents. 
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iii. Anthracyclines are anti-tumor antibiotics that alter the cancer cells DNA, keeping them 
from proliferate and replicate uncontrollably by DNA intercalation or formation of free 
radicals. Two of these antibiotics are doxorubicin [50] and daunorubicin [51] (Figure 7). 
 
 
 
 
 
 
 
iv. Topoisomerase inhibitors influence the DNA strand separation, done by topoisomerase 
enzymes, that arises during S phase and would result on DNA copies at the end of cell 
cycle. Etoposide [52] and teniposide [53] are both inhibitors of this enzyme (Figure 8). 
 
 
 
 
 
 
 
Figure 6. Antimetabolites chemical structures: the examples of methotrexate, pemetrexed and 5-fluorouracil. 
 
Figure 7. Chemical structures of doxorubicin and daunorubicin. Two anti-tumor antibiotics. 
Figure 8. Two examples of topoisomerase inhibitors: chemical structures of etoposide and teniposide. 
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v. Mitotic inhibitors, also known as tubulin-binding drugs, interfere with numerous 
functions of the cell such as mitosis, meiosis, intracellular transport and others. Paclitaxel 
[54], docetaxel [55] and eriblin [56] illustrate this class of drugs (Figure 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to the heterogeneity of most cancers, chemotherapy is usually administrated as a 
combination of the above referred classes of drugs. This procedure intends to overcome cell 
resistance and prevents the generation of new resistant subclones [57]. As a benefit to patients, 
it reduces the side effects of single agents that would have to be used in higher doses in 
monotherapy [38,53]. 
In the last few years, research for cancer cures and treatments have made progresses. 
Targeted agents were recently discovered as potential drug candidates [54,55]. These agents 
widen the therapeutic window, reducing many side effects of traditional procedures as 
chemotherapy and radiotherapy [58]. In 2013, der Hollander and research group described that 
targeted drugs have potential uses as preventive agents [59]. It was revealed that ER-targeting 
drugs, such as tamoxifen, have shown preventive efficacy for ER-positive breast cancer leading 
to and effective reduction in incidence. However, the major problem still remains for triple 
negative breast cancer in which it is necessary to identify possible novel targets, develop non-
Figure 9. Chemical structures of paclitaxel, docetaxel and eribulin, some mitotic inhibitors. 
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toxic drugs that successfully interrupt the activity of these targets and find possible delivery 
systems for these novel preventive therapies [59]. 
 
 
2. ChalĐoŶes 
Chemically described as 1,3-diphenyl-2-propen-1-ones, chalcones 1.1 result from the 
connection of two aromatic rings by a three-carbon α,β-unsaturated carbonyl bond [60] (Figure 
10). An aldol condensation between benzaldehyde and acetophenone in the presence of sodium 
hydroxide as a catalyst is the most efficient method that leads to the preparation of chalcones. 
 
Figure 10. Chalcone. 
 
Chalcones are naturally occurring compounds in edible plants that exhibit a wide-range 
spectrum of biological activities as anti-inflammatory [57,58], antioxidant [63], anti-tubercular 
[64], anti-HIV [65], antimalarial [66], anti-allergic [67], anti-diabetic [68], cardioprotective [69] 
and also anticancer agents through multiple mechanisms [70]. 
 
2.1. Anticancer properties of chalcones  
A general overview of recent works reveals a constant search for naturally occurring 
chalcones with anticancer activity and novel mechanisms of action. Thus, many natural 
chalcones with promising anticancer effectiveness against a diversity of cancer cell lines have 
been identified. 
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Figure 11. Natural and synthetic chalcones with anticancer properties. 
 
Found in Angelica keiskei roots, 4-hydroxyderricin 1.2 (Figure 11) was described as an 
inducer of apoptotic cell death via death receptor-mediated and mitochondrial pathways by 
topoisomerase II inhibition in leukemia cells (HL60) [71]. Furthermore, this chalcone also 
exhibited great cytotoxic properties against another three cancer cell lines: A459 (lung), AZ521 
(stomach) and CRL1579 (melanoma). 
Ye et al. found a novel pyranochalcone 1.3 (Figure 11) with strong cytotoxic effect 
isolated from the seeds of a Chinese medicinal plant, Milletia pachycarpa, showing great 
minimal effective concentration in several cancer cell lines [72]. Moreover, this pyranochalcone 
showed strong apoptosis inducing effects at a concentration of 2 μM ǁithiŶ ϯϲh. 
HTMC 1.4 ;Ϯ’-hydroxy-Ϯ,ϯ,ϰ’,ϲ’-tetramethoxychalcone) (Figure 11) was extracted from a 
medicinal plant Caesalpinia pulcherrima and demonstrated great in vitro selectivity for many 
human lung cancer cell lines [73]. In A549 (lung adenocarcinoma cells), HTMC presented a 
cytotoxic activity by causing G1 phase cell-cycle arrest. 
Naturally occurring chalcones revealed promising anticancer properties that led to many 
synthetically inspired chalcones with enhanced anticancer activity. The manipulation of the aryl 
rings or replacement by scaffolds with heteroaryl/steroidal/alicyclic and conjugation of 
pharmacologically interesting scaffolds through molecular hybridization are the three main used 
strategies to manipulate and enhance the characteristics of chalcones as anticancer agents [74]. 
Zhang et al. described that chalcone 1.5 (Figure 11) presented a remarkable 
antiproliferative potential with very low IC50 values of 0.03 and 0.95 µg/mL for MCF-7 (breast) 
and A549 (lung) cell lines, respectively [75]. At 1.42 µg/mL, this compound also demonstrated 
to be a promising antitubulin polymerization inhibitor. 
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A series of 20 brominated chalcones were designed, prepared and tested in four 
different gastric cancer cell lines [76]. From all the compounds, H72 1.6 (Figure 11) was the one 
that presented more potential with lower IC50 and less cytotoxicity to the normal gastric cell line 
GES-1. The treatment with H72 in MGC803 and HGC27 seems to induce the generation of ROS 
which causes mitochondria mediated apoptosis and activates the caspase 9/3 cascade. 
A synthetic flavonoid derivative, 2'-hydroxy-2,3,5'-trimethoxychalcone 1.7 (DK143) 
(Figure 11) showed evidences to be involved in apoptosis induction by unfolded protein 
response in the breast cancer cell line MDA-MB-231 [77]. The production of ROS (Reactive 
Oxygen Species) and upregulation of ER stress sensors expression are the mechanisms involved 
in the anticancer activity of this synthetic chalcone. DK143 does not affect viability for the non-
transformed cell line MCF10A. In vivo, DK143 suppressed mouse tumor growth. 
 
 
3. ChroŵeŶes aŶd ĐouŵariŶes 
The fusion of a benzene ring with a heterocyclic pyran ring results in a polycyclic 
compound named benzopyran. Chromene was the nomenclature adopted by IUPAC to define 
these compounds. 1-benzopyran (1.8 and 1.9 in Figure 12) and 2-benzopyran (1.10 and 1.11 in 
Figure 11) were the two classes of benzopyrans named by the position of the oxygen atom on 
the pyran ring [78]. Depending on the level of oxidation and saturation, 1-benzopyran may be 
named chroman 1.12, 2H-chromene (2H-1-benzopyran) 1.13, 4H-chromen (4H-1-benzopyran) 
1.14, 2H-chromen-2-one 1.15 and 4H-chromen-4-one 1.16 (Figure 12) [79]. 
 
 
 
Coumarin, also known as 2H-1-benzopyran-2-one or 1,2-benzopyrone (Figure 13), and 
its derivatives are largely disseminated in nature [80]. Present as secondary metabolites in the 
roots, leaves and seeds of several plant species, coumarines have various and advantageous 
biological activities [81]. Regulation of plant growth, bacteriostasis, fungistasis and waste 
products exemplify the not yet completely clear functions of coumarines [81]. 
Figure 12. 1-benzopyrans and 2-benzopyrans. 
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Owing to their natural occurrence, chromenes and coumarin derivatives were studied 
and many therapeutic applications were found including antitumor [60,61], anti-HIV therapy 
[84], antibacterial [85], antifungal [86], anti-inflammatory [87], anti-coagulant [88], antioxidant 
[65,67] and antidepressant [68,69]. It is also reported that coumarines present lipid-lowering 
properties with moderate triglyceride-lowering potential [70,71]. Previously used as fixative and 
flavoring agents, Food and Drug Administration regulated coumarines as food adulterants 
because of their side effects including hepatotoxicity. Several European countries use coumarin 
type drugs for therapeutic purposes and the compounds are administrated to patients with 
lymphedema [72–74]. Additionally, perfumes, cosmetics, dyes and herbicides were also some 
applications of coumarine derivatives in industry [97]. 
 
 
3.1. Anticancer activity of chromenes 
As described above, several studies were conducted to determine the potential 
therapeutic applications of chromenes. Since cancer is a disease that affects the population 
worldwide and chromenes have already proved some anticancer activity, this became an 
interesting research area. Several natural chromenes and synthetic derivatives were tested for 
their anticancer properties both in vivo and in vitro. Their cytotoxic effects and mechanism of 
action were also studied. 
 
 
 
 
3.1.1. Natural chromenes as anticancer agents 
Isolated from Calophyllum dispar fruits and stem barks, coumarins 1.17 and 1.18 (Figure 
14) inhibited 50% of cellular growth in nasopharyngeal carcinoma KB cell lines. The cytotoxic 
effect was found to be more effective in a 4 to 8 µg/mL concentration range [98]. 
Figure 13. Chroman 1.12, 2H-chromene (2H-1-benzopyran) 1.13, 4H-chromen (4H-1-benzopyran) 1.14, 2H-chromen-
2-one 1.15 and 4H-chromen-4-one 1.16. 
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Scio et al. extracted coumarins 1.19a and 1.19b with dichloromethane from the stem 
bark of a Brazilian plant, Kielmeyera albopunctata (Figure 14). These compounds showed active 
anticancer activity against numerous and varied human cancer cell lines such as Lu1 (lung), Col2 
(chondrosarcoma), KB (nasopharyngeal) and LNCaP (prostate), with ED50 from 11.1 to 19.8 
µg/mL [99].   
 
Figure 14. Series of natural products with observed anticancer activity. 
The ethanol extract from the root of Salvia miltiorrhiza led to the isolation of a minor 
compound, neo-tanshinlactone 1.20 (Figure 14). The anticancer properties of this 
chromene were assessed for many breast cancer cell lines and a molecular route was 
proposed for this chromene. In terms of ED50, the molecule showed low values with 
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concentrations ranging from 0.2 to 0.6 µg/mL for MCF-7 and ZR-75-1, both ER+ 
overexpressing cell lines, and for one ER-/HER2 (SK-BR-3) [78,79]. 
17 Chromene-based compounds were extracted from the leaves of a tree native from 
Panama, Costa Rica and Colombia, Marila pluricostata. From this set of compounds, some 
mammeisin derivatives were recognized (chromenes 1.21, 1.22 and 9 examples of chromenes 
1.23) (Figure 14) and some molecules were newly discovered (compounds 1.21, 24a and 1.24b 
with R1 = H and R2 = CH2CHC(CH3)2). This range of compounds exhibited great cytotoxic effect 
(0.1 µg/mL GI50 value) in human cancer cell lines MCF-7, H-480 and SF-268 leading to a promising 
anticancer activity [102].  
Naturally occurring in the Egyptian plant Polygonum senegalense, 5 chromenes 1.25 
(Figure 14) were isolated from the fungal endophyte Alternaria sp. The cytotoxic activity of these 
molecules was studied against lymphoma cells L5178Y and relevant results were found for 
compounds 1.25a-c, with EC50 values of 1.7 to 7.8 µg/mL. The inhibitory potential of these 
chromenes was also assessed in 24 different protein kinases leading to an effective inhibitory 
power for several enzymes. An interesting inhibition of cellular growth was also found for 
concentrations lower than 10 µg/mL [81,82]. 
  Du et al. isolated 15 coumarins 1.26 (Figure 14) from Mammea Americana, a 
tropical/subtropical plant. These compounds showed anticancer activity in human breast and 
prostate cancer cell lines through the inhibition of the activation of HIF-1 (hypoxia-inducible 
factor-1). These molecules demonstrated to have EC50 values lower than 10 µM for human 
breast tumor (T47D) and prostate tumor (PC-3) cell lines. The inhibition of HIF-1 seemed to be 
enhanced by coumarins bearing a 6-prenyl-8-(3-methyloxobutyl) substituent [105]. 
Extracted from the roots of Mallotus resinosus, coumarins 1.27a-c (Figure 14) 
demonstrated a potent antitumor effect by their activity in cleaving DNA. The effectiveness of 
these molecules for DNA cleavage was not extraordinary, however Ma et al. considered that 
these compounds were valuable leads for future synthetic approaches, because of the simplicity 
of their structure and also due to their importance as DNA strand scission agents [106]. 
In 1996, a potent anticancer chromene was isolated from Psoralea corylifolia, psoralidin 
1.28 (Figure 14). This molecule exhibited cytotoxic effects on colon and breast cancer cell lines 
however its activity was more effective against gastric tumor cell lines (SNU-1 and SNU-16) [107]. 
This chromene was also found to have antioxidant [108], antibacterial [109] and antidepressant 
activity [90]. 
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Aiello et al. isolated two new prenylated benzoquinones, thiaplidiaquinones A (1.29) and 
B (1.30) (Figure 14), from Aplidium conicum an ascidian from the Sardinia coast (Italy) [110]. 
These compounds were studied by propidium iodide (PI) staining and flow cytometry assessing 
their cytotoxicity against a human T lymphoma cell line. Thiaplidiaquinones 1.29 and 1.30 were 
demonstrated to have a pro-apoptotic character. The treated cells showed that both 
compounds induced a strong production of intracellular ROS that led to the appearance of 
apoptotic cells. 
Recently, flemingins were isolated from leaves of a tropical native plant of Africa, 
Flemingia grahamiana [111]. Flemingins 1.31a and 1.31c (Figure 14) seemed to present 
cytotoxic activity when tested against MCF-7 breast human cancer cell line with IC50 of 8.9 and 
7.6 µg/mL, respectively. For this reason, authors describe that these compounds could be 
interesting for the development of novel anticancer agents. 
Millepachine 1.32 (Figure 14) is a compound isolated from a leguminosae, Millettia 
pachycarpa, for the first time in 2013 [112]. This compound showed a great anti-proliferative 
activity in HepG2 (human hepatocellular carcinoma) cell line and flow cytometry showed that 
millepachine presents the ability of arresting cells in G2/M phase. When this arrest was 
investigated, the authors found a relation with the inhibition of cyclin-dependent kinase 1 
activity and suggested millepachine induced apoptosis through a mitochondrial apoptotic 
pathway. Consequently, this compound also induced the formation of ROS. Hence, compound 
1.32 may be a potential lead compound for antitumor drugs. 
 
3.1.2. Synthetic chromenes as anticancer agents 
A general overview of some recent articles shows that a large number of chromene 
derivatives have been prepared with enhanced anticancer activity comparing to the natural 
analogues. The main advantage of synthetic chromenes is the reduction of concentrations 
needed to induce an improved cytotoxic effect. 
4-Arylcoumarins 1.33 (Figure 15) were synthetized and tested for their anticancer 
potential [113]. The best results were found for coumarins bearing the substituents R2 = H, R3 = 
OMe, R4 = OH and R1 = H or R1 = OMe that inhibited cellular growth of human T cell leukemia cell 
line (CEM) at a reduced concentration (0.083 and 0.52 µM, respectively). These two compounds 
showed inhibition of microtubule formation through a pro-apoptotic mechanism, however a 
nonapoptotic pathway also demonstrated to be involved in the induction of cell death. 
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Figure 15. Numerous synthetic chromene derivatives with reported anticancer properties. 
 
Di Braccio et al. prepared chromene derivatives 1.34 (Figure 15) and assessed their 
ability to inhibit proliferation and cellular growth in two cell lines (Ehrlich and HeLa cells) [114]. 
In general, the compounds were only active in one of these tests. However, several molecules 
were recognized for their antiproliferative and cytotoxic activities, with low IC50 values in the 
1.74 to 12.9 µM concentration range. The amine moiety and the substituent in the aromatic ring 
affected the activity of the chromenes. The phenylamino and cycloalkylamino groups proved to 
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be the most active amino substituents and the tricyclic nucleus, formed by an extra aromatic 
ring in the chromene moiety, also favored the results. 
A series of DNA-dependent protein kinase (DNA-PK) inhibitors was prepared as an 
attempt to enhance cytotoxicity of DNA-damaging therapies used in cancer therapy [115]. 
Chromenes 1.35 (Figure 15) carrying a heterocyclic amine in position 4 were studied and the IC50 
varied between 1.75 and 11.31 µM. The lower IC50 value (1.75 µM) was found for the chromene 
bearing a morpholine group in C4 and a methoxyl group in position 6 of the aromatic ring. 
Schmidt and co-workers prepared nonesteroidal chromene derivatives 1.36a and 1.36b 
(Figure 15) and described, after assessment against primary human vein endothelial cells, that 
these compounds presented specific inhibitory activity for endothelial cell proliferation [116]. 
These molecules have such relevance because inhibitors of endothelial cell proliferation are 
used as treatment of angiogenic pathologies, including solid tumors. 
Blagg et al. [95–97] and Bras and co-workers [120] prepared and evaluated novobiocin 
derivatives 1.37 and 1.38 (Figure 15) for their antiproliferative ability and potential heat shock 
protein 90 (Hsp90) inhibitory properties, both as potential targets for new anticancer agents. 
Blagg et al. proved that derivative 1.37, bearing a methyl group in R2 and in C8 of R1, were potent 
inhibitors of the protein-folding mechanism for Hsp90 [117]. These authors studied the 
antiproliferative action of chromenes 1.37 carrying a substituted biaryl or 2-indolyl group using 
numerous cell lines of breast (SkBr3 and MCF-7), prostate (LNCaP and PC-3), pancreatic (PL45) 
and colon (HCT116) cancer and several promising compounds with low IC50 values were 
identified [96,97]. On the other hand, Bras and co-workers tested derivatives 1.38 without the 
noviose moiety. Varying the substitution pattern in positions 4 and 7 was critical and a tosyl 
moiety in both positions led to the best results. These compounds not only led to degradation 
of Hsp90 client proteins, but also to cell death in MCF-7 cell line [120]. Coumermycin A1 
derivatives 1.39 (Figure 15) were also tested and showed inhibitory power against Hsp90 protein 
folding process [121]. 
Compounds 1.40 (Figure 15) showed antiproliferative effect and inhibitory activity for 
Hsp90, by suppressing HIF-1α ;hǇpoǆia iŶduĐiďle faĐtoƌ alphaͿ ĐlieŶt pƌoteiŶ. These ĐhƌoŵeŶes 
exhibited excellent antiproliferative activity in the nano-molar concentration range for H1299 
cell line (lung carcinoma). The antiangiogenic properties were also studied using zebrafish 
embryos and a dose dependent manner was observed (0.25-ϭ.Ϯϱ μMͿ [122]. 
A variety of neo-tanshinlactone analogues 1.41 (Figure 15) were synthetized and tested 
for their anticancer activity in several breast cancer cell lines (MCF-7, ZR-75-1, MDA-MB-231, 
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HS587T and SK-BR-3), non-small cell lung cancer (A549), skin cancer (A431), prostate cancer (LN-
CaP and PC-3), colon cancer (SW620), nasopharyngeal carcinoma (KB) and vincristine-resistant 
KB subline (KB-VIN) [123].  Chromene 1.41 bearing a methyl group in the R1 position and a methyl 
or ethyl group in the R3 position led to the best inhibition of cell growth and also to the best 
selectivity values, showing that the substitution pattern in the furan and the neighboring 
aromatic ring strongly influenced the activity. This compound showed ED50 of 0.45 µg/mL for 
MCF-7 and 0.18 µg/mL for ZR-75-1. In a different work, the same research group investigated a 
new set of neo-tanshinlactone analogues 1.41, varying the substitution pattern in different ring 
positions [124]. Once again several chromenes were identified as promising anticancer agents 
with low ED50 values (lower than 1 µg/mL). The methyl group in the R1 position and alkyl groups 
in R3 led once again to the best results. 
Dong et al. prepared analogous chromenes 1.42 (Figure 15), bearing an amine moiety in 
C4 instead of a furan ring. The cytotoxicity of these compounds was assessed for several tumor 
cell lines [125]. In terms of substitution pattern, the most advantageous in the tested lines 
showed to be the aromatic, due to the low ED50 values (0.01-5.8 µM). Later, the same authors 
synthetized similar chromenes 1.43 (Figure 15) [126]. These molecules involved a five or six-
membered ring appended to the aromatic chromene unit. On the other hand, chromenes 1.42 
had a second aromatic ring. Compounds combining a six-membered ring and a 4-methoxyphenyl 
group in the amine unit, with R3 = H or Me, presented great cytotoxic effect against different 
human tumor cell lines from diverse tissues, with ED50 values from 0.008 to 0.32 µM. 
Compound 1.44 (Figure 15) described by Chandra and co-workers was studied as an 
inhibitory of hyperplasia formation agent using estradiol-induced rat uterine hyperplasia [127]. 
Atypical hyperplasia and consequent cancer formation in the endometrium was induced by 
estrogen hormones which primarily change the structure of the tissue in the uterus. The 
molecule was injected in the ovariectomized rats at 100 and 200 µg/kg concentrations. The 
results suggest that this chromene induces apoptosis via the intrinsic pathway and inhibits the 
formation estradiol-induced hyperplasia in rat uterus. 
Xing et al. evaluated the cytotoxic effect of 4H-chromene 1.45 and derivatives in various 
tumor cell lines (Figure 15). These authors were mostly interested in compounds that selectively 
target drug-resistant cancer cells to overcome this problem. Cancer cells overexpressing the 
antiapoptotic Bcl-2 family proteins were treated with compound 1.45, with R1 = R2 = Et and R3 = 
H, and they perform an antagonist role for malignant cells indicating selective cytotoxicity and 
overcome drug resistance [106,107]. This compound induced cell death through the 
endoplasmatic reticulum (ER) pathway, causing stress and ER Ca2+ release. Compound 1.45 with 
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R1 = R2 = Et and R3 = 3,5-OMe led to more promising results and demonstrated lower micromolar 
cytotoxicity against a series of hematologic and solid tumor cells (11 different cancer cell lines) 
[108,109]. The performance of this chromene was also assessed in two drug-resistant cancer 
cells for camptothecin (CCRF-CEM/C2) and mitoxantrone (HL-60/MX2) and selectively killed 
these resilient cells over parent cancer cells. A structure-activity relationship study resulted in 
the synthesis of other analogues of compound 1.45, bearing similar substitution pattern in R3 as 
the former compound, but with R1 = R2 = CH2C≡CH [131]. This compound presented improved 
activity in the drug resistant HL60/MX2 human leukemia cell line with an IC50 value of 640 nM. 
The activation of HIF pathway aids tumor cells to adapt to low levels of oxygen (hypoxia), 
leads to therapeutic resistance and has become a vital target for several cancer therapies. 2H-
Chromenes 1.46 (Figure 15) demonstrated to inhibit HIF-1, when assessed against LN229-HRE-
Lux (human glioma cell line) using hypoxia conditions [110,111]. The substitution pattern was 
studied and when R2 = phenyl group and the R1 substituent was varied between a 3,4-
dimethoxyphenyl, 4-methoxyphenyl or 3,5-dimethylphenyl moiety, IC50 values were lower (nM 
range). It was demonstrated that when compound 1.46 bare a sulfone group a 3,4-
dimethoxyphenyl and an aromatic ring in the amine moiety (IC50 value of 650 nM) the levels of 
HIF-1 were not modified, though the ability of HIF-1α/HIF-1β to interact with cofactors 
p300/CBP was affected interfering with the creation of an active transcriptional complex.  
2H-Chromene 1.47 (Figure 15) were also evaluated as possible anticancer agents, using 
four human cell lines: chronic myelogenous leukemia (K562), alveolar basal epithelial 
adenocarcinoma (A549), acute lymphoblastic leukemia (MOLT-4) and breast adenocarcinoma 
(MCF-7) [134]. The chromene with R1 = 6-Br and a hydantoin moiety in the 3-position (X = O, Y = 
NH and R2 = H) led to the best results, with similar IC50 values to a common anticancer agent, 
cisplatin. 
A series of homoisoflavonoid derivatives 1.48 (Figure 15) were investigated against 
three human breast cancer cell lines including MCF-7, T47D and MDA-MB-231 by a MTT assay 
and acridine orange/ethidium bromide double staining technique [135]. From the results of the 
MTT assay results, researchers concluded that these derivatives had high activity against MCF-
7, T47D and MDA-MB-231 cell lines with IC50 ǀalues of ϲ.Ϯ±Ϭ.ϭ, ϰ.ϲ±Ϭ.ϭ, aŶd ϵ.ϯ±Ϯ.ϭ μg/ŵl, 
respectively. However, the cytotoxic power of the compound seems to be influenced by the 
presence of benzo[d][1,3]dioxole in the benzylidene moiety, decreasing it. According to the 
results of the double staining technique with acridine orange and ethidium bromide, these 
compounds may induce apoptosis in cancer cell lines by nuclear DNA fragmentation. 
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 Hematoxylin is a natural compound that demonstrated to have an inhibitory power 
against tyrosine kinases and in vitro antitumor activity. Hematoxylin analogue DW534 
(compound 1.49 in Figure 15) was synthetized and tested in different cell lines such as HT-29 
(human colorectal adenocarcinoma), K562 (human erythromyeloblastoid leukemia), T47D 
(human breast cancer), MCF-7 (human breast adenocarcionoma), PC-3 (prostate cancer), HCT-
116 (human colon carcinoma), A549 (human lung carcinoma) and MDAMB-231 (human breast 
cancer), by ELISA assay and Western-Blot. According to the results obtained, DW532 inhibits cell 
growth, arrests cell cycle and leads to apoptosis selectively in cancer cells. It was also 
demonstrated that compound 1.49 suppressed angiogenesis in vitro and in vivo.  
 Some derivatives of compound 1.32 (Figure 14) were recently synthetized and these 
included compound 1.50 (Figure 15) [136]. As it happened with 1.32, this novel compound 
presented activity through cellular arrest in G2/M phase and also a pro-apoptotic effect. The 
major advantage achieved with this synthesis was the reduction of the IC50 value from 2.86 µM, 
in the initial compound 1.32, to 18 nM in 1.50. 
Due to the increasing cancer incidence, research for novel and effective anticancer drugs 
has been growing at the same rate. Thus, chromenes have proven their anticancer properties as 
natural product and the enhanced abilities when synthetized in laboratory. 
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Aiŵs 
 The skills developed over the years by the organic chemistry group at the Chemistry 
Research Center of the University of Minho in the area of chromene chemistry resulted in the 
development of a variety of novel and potentially bioactive molecules, including chromene 
derivatives [82,133–136]. This project was conducted with the general aim to develop synthetic 
methodologies to generate new chromene derivatives with anticancer properties. 
 Inspired by the known anticancer potential of chromenes as well as chalcones and also 
on the results of an in silico screening of the library of chromene-based compounds prepared by 
the research group, a sequential synthetic method will be thought and optimized to allow the 
isolation of these molecules and test them in breast cancer cell lines. The chalcones and 
chromene scaffolds were identified as promising core units by preliminary results and a number 
of derivatives will be prepared by varying the substitution pattern. 
 The synthesized chalcones and chromenes will be first-screened for their anticancer 
potential inhibiting cell survival using luminal and basal-like breast cancer models, MCF-7 and 
HS578t cell lines, respectively [141]. The effects of the most interesting and promising 
compounds will be further characterized by assessing cell viability, cell proliferation, cell 
migration and expression levels of several proteins. Evaluation of the toxicity for the most active 
compounds to normal cells will be also performed using a non-neoplasctic breast MCF-10 cell 
line. 
 
 
 
 
 
 
 
 
 23 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II – CHEMICAL SYNTHESIS: 
RESULTS AND DISCUSSION 
 
 
 
 
 
 
 
 
 
    
Chapter II – Chemical Synthesis 
24 
 
1. ChalĐoŶe derivatives 
 
Our synthetic approach to prepare chromenes requires the synthesis of substituted α,β-
unsaturated carbonyl compounds and this section emphasizes the different procedures that 
have been used to generate these molecules from aromatic aldehydes and acetophenones. 
Several synthetic approaches have been reported, based on the aldol condensation catalyzed 
by base or acid. The aldol condensation catalyzed by base is still the most commonly used 
method for the formation of these structures. This procedure is simple and environmentally 
benign (water and ethanol are the most commonly used solvents) and the product is usually 
isolated in good yield. The basic catalysis is often, due to NaOH, KOH or Ba(OH)2. However, for a 
wider perspective of the extent and importance of the synthesis of these derivatives, some 
relevant studies mediated by catalysts of a different nature will be mentioned. 
In 1999, Daskiewicz et al. synthetized 2-hydroxychalcones by a LiHMDS-mediated 
(LiHMD) aldol condensation combining appropriate acetophenones and benzaldehydes [142]. 
The reaction with the aldehyde occurred after metalation of the ketone, in dry THF. As an 
example, Scheme 1 shows one of these synthesis, carried out during 12 hours at -78ºC. 
 
Scheme 1. 2-Hydroxychalcone synthesis by a LiHMDS-mediated aldol condensation 
 
 In 2013, Dias et al. obtained a wide range of Ϯ’-hydroxychalcones from the combination 
of 2-hydroxyacetophenone and appropriate aromatic aldehydes [138]. The reaction proceeded 
under the typical conditions for the aldol condensation with aqueous base (NaOH), at room 
temperature and an example is presented in Scheme 2. (E)-3-(3-Fluorophenyl)-1-(2-
hydroxyphenyl)prop-2-en-1-one (2.3II) was isolated with a 99.2% yield. This synthetic method 
was very effective and eco-friendly and, as consequence, this will be the main method optimized 
in this thesis. 
 
Scheme 2. “ǇŶthesis of Ϯ’-hydroxychalcones under basic catalysis. 
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One the other hand, acid catalysis for chalcone synthesis is not as common in the 
literature as reactions catalyzed by base. Nevertheless, two reported examples will be 
presented, using Lewis acids (Scheme 3) or protic acids (Scheme 4). 
In 2007, Narender et al. reported the synthesis of numerous chalcones through the 
reaction of different acetophenones and substituted benzaldehyde in dioxane using 0.5 eq of 
BF3-Et2O. The final products (2.3III) were isolated in 75 to 96% yield [143]. Scheme 3 shows the 
synthetic procedure for one of the analogs, synthetized at room temperature. 
 
Scheme 3. Chalcone synthesis under borontrifluoride-etherate catalysis. 
 
In the same year, Konieczny et al. described the synthesis of α,β-unsaturated carbonyl 
compounds with an oxathiolone ring, under acetic acid and sulfuric acid catalysis [144]. As the 
oxathiolone ring was alkali-sensitive in both the starting material and final product, this 
approach was preferable instead of the traditional base-catalyzed Claisen-Schmidt 
condensation. A substituted acetophenone was combined with a substituted benzaldehyde and 
led to the isolation of (E)-6-(3-(3,4-dimethoxyphenyl)acryloyl)-7-methoxybenzo[d][1,3]oxathiol-
2-one (2.3IV) in 50% yield (Scheme 4). 
 
Scheme 4. Acidic catalysis of acetophenone with 3,4-dimethoxybenzaldehyde reaction. 
 
 
1.1. Synthesis and mechanistic discussion 
In this work, the synthesis of α,β-unsaturated carbonyl compounds was performed 
under base-catalyzed aldol condensation conditions. Thus, the reaction of aromatic 
benzaldehydes with acetophenones occurred in EtOH and aqueous NaOH (3M) with magnetic 
stirring, generally, at room temperature (2.3c, 2.3d, 2.3e, 2.3f, 2.3g, 2.3h, 2.3i, 2.3j, 2.3k, 2.3l, 
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2.3m, 2.3n, 2.3o, 2.3p, 2.3r, 2.3s, 2.3t, 2.3u, 2.3v, 2.3w, 2.3x and 2.3z). However, some reactions 
required heating at 40ºC (2.3a, 2.3b and 2.3q) or 60ºC (2.3y) (Table 2). 
 
 
Table 2. General substitution pattern of chalcones 2.3a-z. 
 
 
Comp R1 R2 R3 R4 R5 R6 
2.3a OH OCH3 H Br H H 
2.3b OH OCH3 H Br Cl H 
2.3c OH OCH3 H Br H OCH3 
2.3d OH H H Cl H OCH3 
2.3e OH H H Br H OCH3 
2.3f OH F H F H H 
2.3g OH H H Cl CH3 H 
2.3h OH OCH3 H Br CH3 H 
2.3i OH H H Br Br H 
2.3j OH OCH3 H H Cl H 
2.3k OH H H Br CH3 H 
2.3l OH F H F CH3 H 
2.3m OH OCH3 H Br Br H 
2.3n H H H Br CH3 H 
2.3o OH H H H H H 
2.3p OH OCH3 H H H H 
2.3q OH H H Br H H 
2.3r OH H H Cl Cl H 
2.3s OH F H F Cl H 
2.3t OH H H Cl H H 
2.3u OH H H CH3 Cl H 
2.3v OH H H Br Cl H 
2.3w OH F H F H OCH3 
2.3x OH F H F H Br 
2.3y OH H OCH3 H Cl H 
2.3z OH H H Br F H 
 
 The synthetic mechanism proposed to obtain these compounds was already extensively 
studied and reported in the literature. It involves nucleophilic attack of the enol form from the 
ketone 2.1I to an electrodeficient carbon from the carbonyl of the aldehyde 2.2. This attack leads 
to an intermediate β-hydroxycarbonilic compound 2.4. Finally, dehydration produces the 
respective conjugated enone 2.3 (Scheme 5). As will be described later, some reactions led to 
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the isolation of structure 2.5, where the α,β-unsaturated carbonyl compound further 
incorporated another unit of acetophenone 2.1 by Michael additioŶ to the β-carbon atom. 
 
 
Scheme 5. Synthesis of chalcones 2.3 from substituted acetophenones and benzaldehydes  
 
Table 3. Physical and analytical data for chalcones 2.3a-z. 
Comp R1 R2 η ;%Ϳ m.p. (ºC) Molecular 
Formula/Weight 
2.3a H 2-OH;3-OCH3;5-Br 99.7 175-177 C16H15BrO3/335.2gmol-1 
2.3b ϰ’-Cl 2-OH;3-OCH3;5-Br 65.6 163-165 C16H15BrClO3/369.6gmol-1 
2.3c ϯ’-OCH3 2-OH;3-OCH3;5-Br 99.7 148-150 C17H17BrO4/365.2gmol-1 
2.3d ϯ’-OCH3 2-OH;5-Cl 86.0 158-159.5 C16H15ClO3/290.1gmol-1 
2.3e ϯ’-OCH3 2-OH;5-Br 81.8 162-164 C16H15BrO3/335.2gmol-1 
2.3f H 2-OH;3,5-F 75.0 180-181.5 C15H14F2O2/262.1gmol-1 
2.3g ϰ’-CH3 2-OH;5-Cl 87.3 179-181 C16H15ClO2/274.1gmol-1 
2.3h ϰ’-CH3 2-OH;3-OCH3;5-Br 76.6 192.6-195 C17H17BrO3/349.2gmol-1 
2.3i ϰ’-Br 2-OH;5-Br 70.0 171-173 C15H12Br2O2/384.1gmol-1 
2.3j ϰ’-Cl 2-OH,3-OCH3 83.8 141.5-143 C16H15ClO3/290.7gmol-1 
2.3k ϰ’-CH3 2-OH;5-Br 77.8 191-193 C16H15BrO2/319.2gmol-1 
2.3l ϰ’-CH3 2-OH;3,5-F 78.8 202-204 C16H14F2O2/276.3gmol-1 
2.3m ϰ’-Br 2-OH;3-OCH3;5-Br 80.3 189-191 C16H14Br2O3/414.1gmol-1 
2.3n ϰ’-CH3 5-Br 96.8 127-128.5 C16H15BrO/302.2gmol-1 
2.3o H 2-OH 48.4 169-171 C15H14O2/226.3gmol-1 
2.3p H 2-OH,3-OCH3 94.0 262-264 C16H16O3/256.3gmol-1 
2.3q H 2-OH;5-Br 85.2* - C15H13BrO2/304.2gmol-1 
2.3r ϰ’-Cl 2-OH;5-Cl  165-167 C15H12Cl2O2/295.2gmol-1 
2.3s ϰ’-Cl 2-OH;3,5-F 63.4* - C15H14ClF2O2/296.7gmol-1 
2.3t H 2-OH;5-Cl 87.3* - C15H13ClO2/260.7gmol-1 
2.3u ϰ’-Cl 2-OH;5-CH3 43.0* - C16H15ClO2/304.2gmol-1 
2.3v ϰ’-Cl 2-OH;5-Br 75.2* - C15H12BrClO2/339.6gmol-1 
2.3w ϯ’-OCH3 2-OH;3,5-F 39.2* - C16H14F2O3/292.3gmol-1 
2.3x ϰ’-Br 2-OH;3,5-F 38.6* - C15H11BrF2O2/340.1gmol-1 
2.3y ϰ’-Cl 2-OH;3-OCH3 10.4 156-158 C16H15ClO3/290.1gmol-1 
2.3z ϰ’-F 2-OH;5-Br 96.7* - C15H12BrFO2/323.2gmol-1 
* the compound did not present a satisfactory purity degree, according to 1H NMR data. 
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One of the main aims was to vary the substitution pattern in both aromatic rings. 
However, many limitations in the optimization of the reaction conditions were observed. 
Particularly, the reaction of 5-chloro-2-hydroxybenzaldehyde with substituted and non-
substituted acetophenone (Table 4) led usually to complex product mixtures in aqueous base 
and ethanol. Table 4 summarizes the reaction conditions that were used and the corresponding 
product mixtures identified by 1H NMR. 
 
Table 4. Attempted reactions, experimental conditions and obtained products. 
 
 
Experiment Reagent 2.2 Reagent 2.1 Reactional conditions Product by 1H NMR 
1 3.24mmol 
R1=Cl (2.95mmol, 
0.9eq) 
EtOH (10mL) + 3M NaOH (10mL) 
1: 40ºC, 4h 
2: 60ºC, 12h30 
Dark yellow solid  
2.3t : 2.5 : 2.2 (1:0.34:0.33) 
2 3.52mmol 
R1=Cl (3.52mmol, 
1.0eq) 
EtOH (10mL) + 3M NaOH (10mL) 
IKA, 300rpm, 50ºC, 4 days 
Dark oil – complex mixture 
3 3.33mmol 
R1=Cl (3.67mmol, 
1.1eq) 
EtOH (12mL) + 3M NaOH (10mL) 
rt, 19h  
Yellow solid 
2.3t : 2.5 : 2.2 (1:0.41:0.06) 
4 (as 2.3t in 
Section V) 
1.88mmol 
R1=Cl (2.07mmol, 
1.1eq) 
EtOH (6mL) + 3M NaOH (6mL) 
rt, 6h 
Yellow solid ;η=ϴϴ.ϯ%Ϳ 
2.3t and traces of 2.5 
5 1.68mmol 
R1=Cl (1.84mmol, 
1.1eq) 
EtOH (10mL) + 3M NaOH (10mL) 
rt, 19h 
Dark yellow solid 
2.3t : 2.5 : 2.2 (1:0.70:0.06) 
6 1.37mmol 
R1=H (1.50mmol, 
1.1eq) 
EtOH (5mL) + 3M NaOH (5mL) 
rt, 19h 
Yellow solid 
2.3r : 2.5 : 2.2 (1:0.15:0.06) 
7 2.05mmol 
R1=H (2.25mmol, 
1.1eq) 
EtOH (12mL) + 3M NaOH (12mL) 
rt, 19h 
Dark yellow solid 
2.3r : 2.5 (1:0.43) 
8 2.05mmol 
R1=H (2.05mmol, 
1.0eq) 
EtOH (10mL) + 3M NaOH (10mL) 
rt, 19h 
Dark yellow solid 
2.3r : 2.5 (1:0.39) 
9 2.05mmol 
R1=H (2.05mmol, 
1.0eq) 
EtOH (12mL) + 0.5M NaOH (12mL) 
rt, 16h 
Light yellow solid 
2.3r : 2.2 (1:0.02) 
10 (as 2.3r 
in Section V) 
3.17mmol 
R1=H (3.49mmol, 
1.1eq) 
EtOH (10mL) + 3M NaOH (10mL) 
rt, 24h 
Yellow solid ;η=ϳϭ.Ϭ%Ϳ 
2.3r and traces of 2.5 
11 2.05mmol 
R1=H (2.25mmol, 
1.1eq) 
EtOH (14mL) + 3M NaOH (14mL) 
rt, 5h 
Yellow solid 
2.3r : 2.5 : 2.1 (1:0.06:0.10) 
 
 Comparing experiments 3 and 5, in which the experimental conditions were identical in 
terms of time (19h) and temperature (rt) however, the concentration of the reagents in 
experiment 5 was approximately half of the concentration used in experiment 3. Regarding the 
final products, the molar ratio shows that in experiment 5 the proportion of 2.5 is almost 
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doubled in comparison to experiment 3, when compared to the desired product 2.3t. This 
observation indicated that in dilute solution, the α,β-unsaturated carbonyl compound 2.3t is 
more prone to nucleophilic attack than the salicylic aldehyde used as starting material. This leads 
to a higher yield of adduct 2.5 in experiment 5. Experiments 6 and 7 were performed under the 
same reaction conditions (time and temperature) using unsubstituted acetophenone. The 
concentration of the reagents in experiment 6 is almost twice the concentration used in 
experiment 7. Once again, dilution seems to favor the formation of the adduct 2.5 as was also 
previously observed for experiments 3 and 5. 
 Regarding experiments 3 and 4 where the concentration of reagents is similar, the only 
factor that varies, is the time of reaction (19h and 6h, respectively). The results indicate that the 
desired product 2.3t is isolated with only traces of 2.5 after 6 hours of reaction while in 
experiment 3, after 19 hours, this product appears to be contaminated with almost 41% of the 
adduct 2.5. 
 Reaction time was also an important factor in the synthesis of 2.3r, as after 16h at rt the 
product was isolated with only 2% of the adduct 2.5. When the reaction was extended for a 
further 3h (Experiment 7) the reaction mixture contained 43% of 2.5, together with the desired 
product 2.3r. 
 This study allowed to select the best experimental conditions to prepare compounds 
2.3t and 2.3r (experiments 4 and 10 respectively).  
 
1.2. Spectroscopic characterization 
The structure of compounds 2.3 was assessed by 1H, 13C NMR and IR spectroscopic data, 
summarized in Tables 10 to 14. 
 
Infrared spectroscopy 
Regarding the IR spectroscopic data (Table 5), the stretching vibration of the carbonyl 
group (C=O) varies from 1615 to 1676 cm-1 a relatively low value compared with the standard 
value for isolated carbonyl groups [145]. This low wavenumber might be due to the conjugation 
with the double bond and the aromatic ring. 
For all the compounds, except 2.3n, a peak was identified around 3085-3383 cm-1 
assigned to the stretching vibration of the OH bond, confirming the presence of the hydroxyl 
Chapter II – Chemical Synthesis 
30 
 
group. As reported in Table 5, compound 2.3n does not present any hydroxyl group and this 
peak is absent on the IR spectrum 
 
Table 5. Infrared spectroscopic data (Nujol, cm-1) for chalcones 2.3a-p and 2.3y 
 
 
Comp R1 R2 4000-3000 C=O 1700-1500 
2.3a H 2-OH;3-OCH3;5-Br 3359m 1657s 1585s; 1574s 
2.3b ϰ’-Cl 2-OH;3-OCH3;5-Br 3343m 1657m 1597s 
2.3c ϯ’-OCH3 2-OH;3-OCH3;5-Br 3292m 1649s 1581s 
2.3d ϯ’-OCH3 2-OH;5-Cl 3281w 1643s 1573s 
2.3e ϯ’-OCH3 2-OH;5-Br 3270m 1676s 1644s; 1599s; 1572w 
2.3f H 2-OH;3,5-F 3210m 1650s 1595s; 1572s 
2.3g ϰ’-CH3 2-OH;5-Cl 3085m 1644s 1606m; 1557s 
2.3h ϰ’-CH3 2-OH;3-OCH3;5-Br 3299w 1654s 1607m; 1588m 
2.3i ϰ’-Br 2-OH;5-Br 3285m 1645s 1593s; 1568s; 1554w 
2.3j ϰ’-Cl 2-OH,3-OCH3 3274m 1652m 1584m 
2.3k ϰ’-CH3 2-OH;5-Br 3375w 1644s 1606m; 1559s 
2.3l ϰ’-CH3 2-OH;3,5-F 3151m 1649s 1607m; 1587s; 1565w 
2.3m ϰ’-Br 2-OH;3-OCH3;5-Br 3324m 1656s 1596s; 1578s 
2.3n ϰ’-CH3 5-Br - 1665m 1602m 
2.3o H 2-OH 3364m 1655s 1598m; 1586s; 1569w 
2.3p H 2-OH,3-OCH3 3383w 1632s 1598m; 1580m; 1560m 
2.3y ϰ’-Cl 2-OH;3-OCH3 3278w 1615s 1588s; 1573s; 1539s 
 
 
1H NMR Spectroscopy 
In the 1H NMR spectrum of α,β-unsaturated carbonyl compounds 2.3, the proton of the 
hydroxyl group (-OHͿ appeaƌs as a siŶglet at δ ϵ.ϰϱ–10.60 ppm reflecting the acidity of the 
phenolic proton. As can be seen in Table 6, compound 2.3n does not present this signal 
confirming the absence of this proton in the structure. 
Protons Hα and Hβ, both appear as doublets ďetǁeeŶ δ ϳ.ϴϭ-ϴ.Ϭϯ ppŵ aŶd δ ϳ.ϴϴ-8.09 
ppm, respectively, with a coupling constant between 15.6 and 16.0Hz, confirming the trans 
configuration of the alkene. 
The detailed data for all the compounds is combined in Table 6. 
 
α 
β 
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Table 6. 1H NMR (400 MHz, DMSO-d6, δ ppm) spectroscopy data for chalcones 2.3 
 
Compound R1 R2 Hα Hβ Ar1-H (Ring A) Ar-H (Ring B) 
2.3a H 
2-OH;3-
OCH3;5-Br 
8.03 (d, 
J=15.6Hz) 
7.88 (d, 
J=15.6Hz) 
7.65 (tt, J=1.3Hz, 1H, 
Hϰ’), 8.13 (d, J=6.8Hz, 
1H, Hϲ’) 
3.85 (s, 3H, -OCH3), 7.17 (d, 
J=2.0Hz,1H, H4), 7.77 (d, 
J=2.4Hz, 1H, H6), 9.74 (s, 1H, -
OH) 
2.3b ϰ’-Cl 2-OH;3-
OCH3;5-Br 
8.00 (d, 
J=16.0Hz) 
7.91 (d, 
J=16.0Hz) 
7.63 (dt, J=8.4Hz, 1H, 
Hϱ’), 8.18 (d, J=6.0Hz, 
1H, Hϲ’) 
3.85 (s, 3H, -OCH3), 7.17 (d, 
J=2.4Hz, 1H, H4), 7.77 (d, J= 
2.0Hz, 1H, H6), 9.77 (s, 1H, -OH) 
2.3c 
ϯ’-
OCH3 
2-OH;3-
OCH3;5-Br 
7.88 (d, 
J=15.6Hz) 
7.98 (d, 
J=15.6Hz) 
3.84 (s, 3H, -OCH3), 
7.59 (dd, J=2.8, 
1.6Hz, 1H, HϮ’), 7.23 
(dd, J=8.4, 2.8Hz, 1H, 
Hϰ’), 7.47 (t, J=8.0Hz, 
1H, Hϱ’), 7.75 (d, 
J=1.2Hz, 1H, Hϲ’) 
3.84 (s, 3H, -OCH3), 7.17 (d, 
J=2.4Hz, 1H, H4), 7.77 (d, 
J=2.4Hz, 1H, H5), 9.75 (s, 1H, -
OH) 
2.3d 
ϯ’-
OCH3 
2-OH;5-Cl 
7.92 (d, 
J=16.0Hz) 
7.96 (d, 
J=16.0Hz) 
3.84 (s, 3H, -OCH3), 
7.60 (dd, J=1.6, 
1.2Hz, 1H, HϮ’), 7.37 
(d, J=7.6Hz, 1H, Hϰ’), 
7.48 (t, J=8.0Hz, 1H, 
Hϱ’), 7.24 (dd, J=5.6, 
2.8Hz, 1H, Hϲ’) 
6.95 (d, J=8.8Hz, 1H, H3), 7.30 
(dd, J=8.8, 2.4Hz, 1H, H4), 8.03 
(d, J=2.8Hz, 1H, H5), 10.55 (s, 
1H, -OH) 
2.3e 
ϯ’-
OCH3 
2-OH;5-Br 
7.92 (d, 
J=15.6Hz) 
7.96 (d, 
J=15.6Hz) 
3.84 (s, 3H, -OCH3), 
7.60 (q, J=1.6Hz, 1H, 
HϮ’), 7.37 (dt, J=7.6, 
1.6Hz, 1H, Hϰ’), 7.48 
(t, J=, 8.0Hz, 1H, Hϱ’), 
7.23 (dd, J=5.6, 
2.8Hz, 1H, Hϲ’) 
6.90 (d, J=8.8Hz, 1H, H3), 7.42 
(dd, J=8.8, 2.4Hz, 1H, H4), 8.13 
(d, J=2.4Hz, 1H, H5), 10.60 (s, 
1H, -OH) 
2.3f H 2-OH;3,5-F 
8.03 (dd, 
J=15.6, 
1.2Hz) 
7.97 (d, 
J=15.6Hz) 
7.65 (m, 1H, Hϰ’), 
7.57 (t, J=7.2Hz, 2H, 
Hϯ’+Hϱ’), 8.14 (d, 
J=7.2Hz, 2H, HϮ’+Hϲ’) 
7.33 (m, 1H, H4), 7.77 (m, 1H, 
H6), 10.33 (s, 1H, -OH) 
2.3g 
ϰ’-
CH3 
2-OH;5-Cl 
7.94 (d, 
J=16.0Hz) 
7.93 (d, 
J=16.0Hz) 
8.06 (q, J=6.4, 1.6Hz, 
2H, HϮ’+Hϲ’), 7.37 (d, 
J=8.0Hz, 2H, Hϯ’+Hϱ’),  
2.39 (s, 3H, -CH3), 6.97 (d, 
J=8.8Hz, 1H, H3), 7.28 (dd, J=8.8, 
2.8Hz, 1H, H4), 10.58 (s, 1H, -
OH) 
2.3h 
ϰ’-
CH3 
2-OH;3-
OCH3;5-Br 
7.97 (d, 
J=16.0Hz) 
7.90 (d, 
16.0Hz) 
2.39 (s, 3H, -CH3), 
7.37 (d, J=8.0Hz, 2H, 
Hϯ’+Hϱ’), 8.07 (d, 
J=8.0Hz, 2H, HϮ’+Hϲ’) 
3.85 (s, 3H, -OCH3), 7.17 (d, 
J=2.4Hz, 1H, H4), 7.76 (d, J= 
2.0Hz, 1H, H6), 9.71 (s, 1H, -OH) 
2.3i ϰ’-Br 2-OH;5-Br 7.83 (d, 
J=15.6Hz) 
7.86 (d, 
J=15.6Hz) 
7.67 (d, J=6.8Hz, 2H, 
Hϯ’+Hϱ’), 7.98 (d, 
J=6.4Hz, 2H, HϮ’+Hϲ’) 
6.79 (d, J=8.8Hz, 1H, H3), 7.31 
(dd, J=8.8, 2.4Hz, 1H, H4), 8.04 
(d, J= 2.4Hz, 1H, H6), 10.49 (s, 
1H, -OH) 
2.3j ϰ’-Cl 2-OH,3-OCH3 7.81 (d, 
J=16.0Hz) 
8.09 (d, 
J=16.0Hz) 
8.12 (d, J=6.4Hz, 2H, 
Hϯ’+Hϱ’), 7.63 (d, 
J=8.8Hz, 2H, HϮ’+Hϲ’) 
3.83 (s, 3H, -OCH3), 6.89 (d, 
J=8.8Hz, 1H, H4), 7.05 (dd, J=8.0, 
0.8Hz, 1H, H5), 6.83 (t, J= 8.0Hz, 
1H, H6), 9.47 (s, 1H, -OH) 
2.3k 
ϰ’-
CH3 
2-OH;5-Br 
7.93 (d, 
J=16.0Hz) 
7.94 (d, 
J=16.0Hz) 
2.40 (s, 3H, -CH3), 
7.37 (d, J=8.0Hz, 2H, 
6.89 (d, J=8.8Hz, 1H, H3), 7.40 
(dd, J=8.8, 2.4Hz, 1H, H4), 8.13 
α 
β 
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Hϯ’+Hϱ’), 8.06 (d, 
J=8.0Hz, 2H, HϮ’+Hϲ’) 
(d, J= 2.4Hz, 1H, H6), 10.55 (s, 
1H, -OH) 
2.3l 
ϰ’-
CH3 
2-OH;3,5-F 
8.01 (dd, 
J=15.6, 
1.6Hz) 
7.95 (d, 
J=15.6Hz) 
2.40 (s, 3H, -CH3), 
7.38 (d, J=8.0Hz, 2H, 
Hϯ’+Hϱ’), 8.07 (d, 
J=8.4Hz, 2H, HϮ’+Hϲ’) 
7.32 (m, 1H, H4), 7.75 (m, 1H, 
H6), 10.30 (s, 1H, -OH) 
2.3m ϰ’-Br 2-OH;3-
OCH3;5-Br 
7.91 (d, 
J=16.0Hz) 
8.05 (d, 
J=16.0Hz) 
7.79 (d, J=8.8Hz, 2H, 
Hϯ’+Hϱ’), 8.11 (d, 
J=8.4Hz, 2H, HϮ’+Hϲ’) 
3.86 (s, 3H, -OCH3), 7.19 (d, 
J=2.4Hz, 1H, H4), 7.78 (d, J= 
3.2Hz, 1H, H6), 9.79 (s, 1H, -OH) 
2.3n 
ϰ’-
CH3 
5-Br 
8.00 (d, 
J=15.6Hz) 
7.69 (d, 
J=15.6Hz) 
2.40 (s, 3H, -CH3), 
7.38 (d, J=7.2Hz, 2H, 
Hϯ’+Hϱ’), 8.10 (d, 
J=8.4Hz, 2H, HϮ’+Hϲ’) 
7.85 (d, J=7.6Hz, 1H, H2), 7.42 
(d, J=8.0Hz, 1H, H3), 7.63 (m, 
1H, H4), 8.04 (t, J= 1.6Hz, 1H, 
H6) 
2.3o H 2-OH 
7.86 (d, 
J=16.0Hz) 
8.02 (d, 
J=16.0Hz) 
7.79 (d, J=8.8Hz, 2H, 
Hϯ’+Hϱ’), 7.56 (t, 
J=7.2Hz, 2H, HϮ’+Hϲ’) 
6.95 (dd, J=8.0, 0.8Hz, 1H, H3), 
7.27 (td, J=7.2, 1.6, 1H, H4), 6.87 
(t, J= 7.6Hz, 1H, H5), 7.84 (dd, J= 
8.0, 1.6Hz, 1H, H6), 10.29 (s, 1H, 
-OH) 
2.3p H 2-OH,3-OCH3 
7.83 (d, 
J=16.0Hz) 
7.90 (d, 
J=16.0Hz) 
7.92 (d, J=8.0Hz, 2H, 
Hϯ’+Hϱ’), 7.50 (t, 
J=7.2Hz, 2H, HϮ’+Hϲ’) 
3.60 (s, 3H, -OCH3), 6.43 (dd, 
J=7.6, 1.6Hz, 1H, H4), 6.87 (dd, 
J=8.0, 1.6Hz, 1H, H5), 6.83 (t, 
J=1.6Hz, 1H, H6), 10.03(s, 1H, -
OH) 
2.3q (a) H 2-OH;5-Br 
7.97 (d, 
J=16.0Hz) 
7.95 (d, 
J=16.0Hz) 
7.40 (dd, J=8.8, 
2.4Hz, 1H, H4’), 7.92 
(d, J=8.0Hz, 2H, 
Hϯ’+Hϱ’), 8.13 (d, 
J=4.8Hz, 2H, HϮ’+Hϲ’) 
6.90 (d, J=8.8Hz, 1H, H3), 7.42 
(dd, J=8.8, 2.4Hz, 1H, H4), 7.56 
(t, J= 6.4Hz, 1H, H5), 8.15 (d, J= 
4.8Hz, 1H, H6), 10.56 (s, 1H, -
OH) 
2.3r(a) ϰ’-Cl 2-OH;5-Cl 7.97 (d, 
J=16.0Hz) 
7.94 (d, 
J=16.0Hz) 
7.57 (d, J=8.4Hz, 2H, 
Hϯ’+Hϱ’), 8.17 (d, 
J=8.8Hz, 2H, HϮ’+Hϲ’) 
6.98 (d, J=8.8Hz, 1H, H3), 7.31 
(dd, J=8.8, 2.4, 1H, H4), 7.63 (d, 
J= 8.4Hz, 1H, H6), 10.64 (s, 1H, -
OH) 
2.3s(b) ϰ’-Cl 2-OH;3,5-F     
2.3t(a) H 2-OH;5-Cl 
7.94 (d, 
J=16.0Hz) 
7.97 (d, 
J=16.0Hz) 
8.14 (d, J=8.8Hz, 2H, 
Hϯ’+Hϱ’), 7.56 (t, 
J=7.6Hz, 2H, HϮ’+Hϲ’) 
6.96 (d, J=8.0Hz, 1H, H3), 7.65 
(t, J=7.2Hz 1H, H4), 7.30 (dd, J= 
8.8, 2.8Hz, 1H, H6), 10.57 (s, 1H, 
-OH) 
2.3u(a) ϰ’-Cl 2-OH;5-CH3 8.01 (d, 
J=15.6Hz) 
7.82 (d, 
J=15.6Hz) 
7.56 (d, J=8.4Hz, 2H, 
Hϯ’+Hϱ’), 8.12 (d, 
J=8.4Hz, 2H, HϮ’+Hϲ’) 
2.24 (s, 3H, CH3), 6.84 (d, 
J=8.4Hz, 1H, H3), 7.27 (dd, J=8.4, 
2.0, 1H, H4), 7.63 (dd, J= 8.4, 
2.0Hz, 1H, H6), 10.05 (s, 1H, -
OH) 
2.3v(a) ϰ’-Cl 2-OH;5-Br 7.97 (d, 
J=15.6Hz) 
7.93 (d, 
J=15.6Hz) 
8.18 (d, J=8.8Hz, 2H, 
Hϯ’+Hϱ’), 7.95 (d, 
J=7.6Hz, 2H, HϮ’+Hϲ’) 
6.84 (d, J=8.4Hz, 1H, H3), 7.27 
(dd, J=8.4, 2.0, 1H, H4), 7.63 (dd, 
J= 8.4, 2.0Hz, 1H, H6), 10.05 (s, 
1H, -OH) 
2.3w(a) 
ϯ’-
OCH3 
2-OH;3,5-F 
8.03 (dd, 
J=16.0, 
1.6Hz) 
7.94 (d, 
J=16.0Hz) 
3.80 (s, 3H, OCH3), 
7.60 (t, J=2.0Hz, 1H, 
HϮ’), 7.37 (d, J=7.6Hz, 
1H, Hϰ’), 7.48 (t, J=, 
8.0Hz, 1H, Hϱ’), 7.25 
(dd, J=5.6, 2.8Hz, 1H, 
Hϲ’) 
7.33 (ddd, J=11.2, 2.8Hz, 1H, 
H4), 7.77 (m, 1H, H6), 10.32 (s, 
1H, -OH) 
2.3x(a) ϰ’-Br 2-OH;3,5-F 
8.00 (dd, 
J=15.6, 
1.6Hz) 
7.95 (d, 
J=15.6Hz) 
7.77 (d, J=8.8Hz, 2H, 
Hϯ’+Hϱ’), 8.10 (d, 
J=8.8Hz, 2H, HϮ’+Hϲ’) 
7.34 (ddd, J=11.2, 2.8Hz, 1H, 
H4), 7.76 (m, 1H, H6), 10.35 (s, 
1H, -OH) 
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(a)
 Bands were identified from a mixture of products. 
(b)
 The 1H NMR presented a complex mixture of signals, thus it was not possible to identify with accuracy the signals 
corresponding to the pure product. 
 
  
13 C NMR Spectroscopy 
 Compounds 2.3 were characterized by 13C spectroscopy an analytical chemistry 
technique used to confirm the structure and purity of a sample. This method showed that the 
carbon from the carbonyl group (C=O) varied between δ ϭϴϴ.Ϭϭ–189.50 ppm (Table 7). The 
chemical shift for Cα and Cβ varies in the range δ ϭϮϬ.ϳϯ-ϭϮϯ.ϳϯ ppŵ aŶd δ ϭϯϲ.Ϯϳ-141.83 ppm 
respectively. Finally, C2 generally associated to the hydroxyl group (-OH), presents a chemical 
shift between δ 141.10 ppm and 157.25 ppm. On the other hand, for compound 2.3n, the same 
carbon is observed at δ ϭ28.22 ppm. 
  
Table 7. 13C NMR (100 MHz, DMSO-d6, δ ppm) spectroscopy data for chalcones 2.3. 
 
 
2.3y(a) ϰ’-Cl 2-OH;3-OCH3 7.72 (d, 
J=15.6Hz) 
8.02 (d, 
J=15.6Hz) 
7.62 (dd, J=8.8, 
2.0Hz, 2H, Hϯ’+Hϱ’), 
8.09 (dd, J=8.8, 
2.0Hz, 2H, HϮ’+Hϲ’) 
3.75 (s, 3H, -OCH3), 6.50 (d, 
J=2.4Hz, 1H, H4), 6.48 (d, 
J=2.4Hz, 1H, H5), 7.82 (d, J= 
9.6Hz, 1H, H6), 10.43 (s, 1H, -
OH) 
2.3z(b) ϰ’-F 2-OH;5-Br     
Comp R1 R2 Cα Cβ C=O Ar1-H (Ring A) Ar-H (Ring B) 
2.3a H 
2-OH;3-
OCH3;5-Br 
122.09 137.34 189.17 
128.51 (CϮ’+Cϲ’), 128.72 
(Cϯ’+Cϱ’), 133.08 (Cϰ’), 
137.60 (Cϭ’) 
56.36 (-OCH3), 123.20 
(C1), 149.04 (C2), 145.93 
(C3), 116.14 (C4), 110.50 
(C5), 121.49 (C6) 
2.3b ϰ’-Cl 2-OH;3-
OCH3;5-Br 
121.67 137.75 188.01 
128.84 (CϮ’+Cϲ’), 130.45 
(Cϯ’+Cϱ’), 136.24 (Cϰ’) 
138.06 (Cϭ’) 
56.37 (-OCH3), 123.09 
(C1), 146.03 (C2), 149.05 
(C3), 116.26 (C4), 110.59 
(C5), 121.47 (C6) 
2.3c 
ϯ’-
OCH3 
2-OH;3-
OCH3;5-Br 
122.12 137.43 188.92 
55.36 (-OCH3), 139.05 
(C1’), 113.06 (C2’), 
159.52 (C3’), 121.07 
(C4’), 129.87 (C5’), 
119.06 (C6’) 
56.36 (-OCH3), 123.19 
(C1), 145.94 (C2), 149.03 
(C3), 116.16 (C4), 110.57 
(C5), 121.51 (C6) 
2.3d 
ϯ’-
OCH3 
2-OH;5-Cl 122.05 137.67 188.95 
55.28 (-OCH3), 139.08 
(C1’), 113.05 (C2’), 
159.53 (C3’), 121.04 
(C4’), 129.88 (C5’), 
119.05 (C6’) 
123.05 (C1), 155.95 (C2), 
117.85 (C3), 131.40 (C4), 
123.23 (C5), 127.47 (C6) 
α 
β 
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2.3e 
ϯ’-
OCH3 
2-OH;5-Br 122.03 137.60 188.95 
55.37 (-OCH3), 139.09 
(C1’), 113.06 (C2’), 
159.54 (C3’), 121.07 
(C4’), 129.89 (C5’), 
119.05 (C6’) 
123.13 (C1), 155.92 (C2), 
117.86 (C3), 131.24 (C4), 
123.19 (C5), 127.40 (C6) 
2.3f H 2-OH;3,5-F 123.29 
136.67 
(t, 
J=3.0Hz) 
188.17 
128.54 (CϮ’+Cϲ’), 128.80 
(Cϯ’+Cϱ’), 133.34 (Cϰ’), 
137.44 (C1’) 
124.94 (dd, J=9.0, 4.0Hz, 
C1), 141.19 (dd, J=11.0, 
3.0Hz, C2), 151.59 (dd, 
J=241.0, 13.0Hz, C3), 
106.28 (dd, J=23.0, 
28.0Hz, C4), 154.33 (dd, 
J=235.7, 11.6Hz, C5), 
109.08 (dd, J=23.0, 4.0Hz, 
C6) 
2.3g 
ϰ’-
CH3 
2-OH;5-Cl 122.04 137.24 188.63 
21.17 (-CH3), 128.65 
(CϮ’+Cϲ’), 129.31 
(Cϯ’+Cϱ’), 143.50 (Cϰ’), 
135.12 (C1’) 
123.13 (C1), 155.92 (C2), 
117.86 (C3), 131.24 (C4), 
123.19 (C5), 127.40 (C6) 
2.3h 
ϰ’-
CH3 
2-OH;3-
OCH3;5-Br 
122.11 136.96 188.58 
21.18 (-CH3), 128.67 
(CϮ’+Cϲ’), 129.30 
(Cϯ’+Cϱ’), 143.52 (Cϰ’), 
135.08 (C1’) 
53.36 (-OCH3), 123.28 
(C1), 145.85 (C2), 149.03 
(C3), 116.06 (C4), 110.57 
(C5), 121.45 (C6) 
2.3i ϰ’-Br 2-OH;5-Br 121.56 137.94 188.24 
130.55 (CϮ’+Cϲ’), 131.80 
(Cϯ’+Cϱ’), 127.25 (Cϰ’), 
136.59 (Cϭ’) 
123.56 (C1), 156.43 (C2), 
118.33 (C3), 134.38 (C4), 
110.85 (C5), 130.34 (C6) 
2.3j ϰ’-Cl 2-OH,3-OCH3 120.73 139.70 188.28 
128.85 (CϮ’+Cϲ’), 130.25 
(Cϯ’+Cϱ’), 136.49 (Cϰ’), 
137.82 (Cϭ’) 
55.95 (-OCH3), 121.51 
(C1), 146.72 (C2), 148.01 
(C3), 113.76 (C4), 119.05 
(C5), 119.82 (C6) 
2.3k 
ϰ’-
CH3 
2-OH;5-Br 122.01 137.11 188.59 
21.17 (-CH3), 128.66 
(CϮ’+Cϲ’), 129.30 
(Cϯ’+Cϱ’), 143.51 (Cϰ’), 
134.09 (C1’) 
123.75 (C1), 156.28 (C2), 
118.28 (C3), 134.09 (C4), 
110.83 (C5), 130.26 (C6) 
2.3l 
ϰ’-
CH3 
2-OH;3,5-F 123.30 
136.27 
(t, 
J=4.0Hz) 
188.55 
21.17 (-CH3), 128.69 
(CϮ’+Cϲ’), 129.36 
(Cϯ’+Cϱ’), 143.72 (Cϰ’), 
134.93 (C1’) 
125.02 (dd, J=10.0, 4.0Hz, 
C1), 141.10 (dd, J=15.0, 
3.0Hz, C2), 151.53 (dd, 
J=240.0, 13.0Hz, C3), 
106.16 (dd, J=23.0, 
28.0Hz, C4), 154.34 (dd, 
J=236.0, 12.0Hz, C5), 
109.02 (dd, J=23.0, 4.0Hz, 
C6) 
2.3m ϰ’-Br 2-OH;3-
OCH3;5-Br 
121.65 137.74 188.23 
130.56 (CϮ’+Cϲ’), 131.80 
(Cϯ’+Cϱ’), 127.27 (Cϰ’), 
136.57 (Cϭ’) 
56.37 (-OCH3), 123.09 
(C1), 149.06 (C2), 146.04 
(C3), 116.27 (C4), 110.59 
(C5), 121.48 (C6) 
2.3n 
ϰ’-
CH3 
5-Br 123.51 141.83 188.40 
21.18 (-CH3), 128.78 
(CϮ’+Cϲ’), 129.34 
(Cϯ’+Cϱ’), 143.79 (Cϰ’), 
134.82 (Cϭ’) 
137.23 (C1), 128.22 (C2), 
130.89 (C3), 132.93 (C4), 
122.36 (C5), 130.76 (C6) 
2.3o H 2-OH 120.92 139.54 189.50 
128.31 (CϮ’+Cϲ’), 128.75 
(Cϯ’+Cϱ’), 132.86 (Cϰ’), 
137.90 (Cϭ’) 
121.33 (C1), 157.25 (C2), 
116.22 (C3), 132.03 (C4), 
119.38 (C5), 128.70 (C6) 
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The assignments were confirmed by the correlation spectra between 1H and 13C NMR 
for all the compounds. It was possible to identify the 3-bond interactions for proton Hα with 
carbon C1 and the weak interaction at two bonds with the carbonyl group and Cβ. It was also 
identified the 4-bonds interaction with carbons C2’ and C5. For proton Hβ, interactions with the 
carbon of the carbonyl group were confirmed as well as with C2. At two bonds, a weak 
interaction was observed with carbon Cα and a weak 4-bonds interaction with carbon Cϭ’ (Figure 
16). 
 
 
 
 
 
2. ϰH-ĐhroŵeŶe derivatives 
The chromene nucleus is widely present in animals and plants and has also been 
intensely studied by the scientific community. Different synthetic approaches were described in 
the literature and the example selected involves the use of salicylaldehyde as starting material 
in the reaction with an electron-deficient alkene. 
In 2013, Yin and co-workers synthetized a series of chromenes from salicylaldehyde 2.1e 
aŶd aŶ eǆĐess of β-nitrostyrene via the oxa-Michael-Henry reaction (Scheme 6) [146]. This 
reaction was catalyzed by L-proline and triethylamine and products 2.6 were obtained in 21 to 
53% yield. A specific compound, 8-methoxy-2-(4-fluorophenyl)-3-nitro-2H-chromene 2.6a 
presented biological activity as a PI3K inhibitor.  
 
 
Scheme 6. Preparation of 8-methoxy-2-(4-fluorophenyl)-3-nitro-2H-chromene and analogues. 
 
 
β 
α 
Figure 16. Interaction by bidimensional correlation of Hα and Hβ with the vicinity, for compounds 2.3. 
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2.1. Synthesis and mechanistic discussion 
In order to synthetize 4H-chromenes from α,β-unsaturated carbonyl compounds 2.3, 
these chalcones were combined with active methylene compounds (methyl cyanoacetate 2.6 or 
malononitrile 2.7) (Scheme 7). Reactions were carried out in the presence of triethylamine, with 
methanol (MeOH) for chromenes 2.9 (Scheme 8) or ethanol (EtOH) for chromenes 2.10 (Scheme 
9) as solvent and stirring at room temperature for a variable number of hours. The reactions 
were followed by TLC and, after the consumption of the limiting reagent, were cooled to -20ºC 
and the solid product was isolated by filtration. 
 
 
Scheme 7. Proposed mechanism for the synthesis of 4H-chromenes from chalcones 2.3 and the active methylene 
compounds. 
 
 
Scheme 8. Simplified reaction of chalcones 2.3 with methyl cyanoactetate 2.7. 
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Table 8. Physical and analytical data for 4H-chromenes 2.10. 
 
 
Almost every experiment in the synthesis of compounds 2.10 resulted in the isolation of 
pure chromenes and with good yield. However, by TLC, in some reactions, it was possible to 
prove that the initial products were consumed but when the reaction mixture was cooled to -
20ºC, even then, the chromene did not precipitate possibly due to the absence of a 
crystallization core.  
 
Scheme 9. Simplified reaction of chalcones 2.3 with malononitrile 2.8. 
 
Table 9. Physical and analytical data for 4H-chromenes 2.11. 
Comp R2 R3 R4 R5 R6 η (%) m.p. (ºC) Molecular Formula/Weight 
2.11a H H H H H 27.0 136.5-138 C18H14N2O2/290.3gmol-1 
2.11b H H Br CH3 H 61.8 183-184.5 C19H15BrN2O2/383.2gmol-1 
2.11c OCH3 H Br H H 41.8 177-179 C19H15BrN2O3/399.2gmol-1 
2.11d OCH3 H Br Cl H 68.1 169-171 C19H14BrClN2O3/433.7gmol-1 
2.11e OCH3 H Br H OCH3 63.8 157-159.5 C20H17BrN2O4/429.3gmol-1 
2.11f H H Cl CH3 H 39.6 175-176.5 C19H15ClN2O2/338.8gmol-1 
2.11g H H Br H OCH3 24.7 134-135 C19H15BrN2O3/399.2gmol-1 
2.11h F H F H H 21.4 149-151 C18H12F2N2O2/326.3gmol-1 
2.11i OCH3 H Br CH3 H 12.1 129-131 C20H17BrN2O3/413.3gmol-1 
2.11j H H Br Br H 50.3 186-188 C18H12Br2N2O2/448.1gmol-1 
2.11k OCH3 H Br Br H 56.6 161-163 C19H14Br2N2O3/478.1gmol-1 
 
 
Comp R2 R3 R4 R5 R6 η ;%Ϳ m.p. (ºC) Molecular Formula/Weight 
2.10a OCH3 H H Cl H 71.8 141-143 C20H18ClNO5/387.8gmol-1 
2.10b H H Br H H 58.5 145-147 C19H16BrNO4/402.2gmol-1 
2.10c OCH3 H Br H OCH3 45.2 159-161 C21H20BrNO6/462.3gmol-1 
2.10d H H Br Cl H 57.1 115-117 C19H15BrClNO4/436.7gmol-1 
2.10e OCH3 H Br H H 69.3 183-184.5 C20H18BrNO5/432.3gmol-1 
2.10f H H Cl H H 56.5 116-118 C19H16ClNO4/357.8gmol-1 
2.10g H H Br Br H 62.3 140-141 C19H15Br2NO4/481.1gmol-1 
2.10h OCH3 H Br Br H 57.1 164-165.5 C20H17Br2NO5/511.2gmol-1 
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 Compared with compounds 2.10, chromenes 2.11 were much easier to precipitate from 
the reaction mixture. Even at room temperature, and when the reaction was not yet concluded, 
the product started to precipitate. However, cooling to -20ºC resulted in an increased yield of 
this product. 
 
 
2.2. Spectroscopic characterization 
 
The structure of compounds 2.10 and 2.11 was assessed by 1H, 13C NMR and IR 
spectroscopic analysis and the data is combined in Tables 10 to 14.  
 
Infrared Spectroscopy  
The infrared spectra of compounds 2.10 and 2.11 show two absorption bands in the 
region from ʋ=3489 to 3204 cm-1 assigned to the NH2 stretching vibration of the amino group 
(Table 10). For the region between 1689 and 1512 cm-1, bands with variable intensity are 
observed, probably due to the stretching vibrations of C=C and C=O. Finally, between 2176 and 
2195 cm-1 we can see the characteristic bands for the stretching vibration of nitrile group (-CN), 
only present in compounds 2.11. 
 
Table 10. Infrared spectroscopic data (Nujol, cm-1) for 4H-chromenes 2.10 and 2.11. 
Comp R2 R3 R4 R5 R6 4000-3000 C≡N 1700-1500 
2.10a OCH3 H H Cl H 3428m; 3316m  1681s; 1664s; 1635m; 1613s; 1583w 
2.10b H H Br H H 3420m; 3300w  1672s; 1656s; 1614m; 1599s; 1581w 
2.10c OCH3 H Br H OCH3 3458i; 3312w  1676s; 1609s; 1580m; 1521s 
2.10d H H Br Cl H 3405m; 3280w  1674s; 1605s; 1584m; 1522s 
2.10e OCH3 H Br H H 3405m; 3281w  1673s; 1605s; 1584m; 1522s 
2.10f H H Cl H H 3416m  1659s; 1603s; 1514m 
2.10g H H Br Br H 3466m  1680s; 1600m; 1516m 
2.10h OCH3 H Br Br H 3404w; 3280w  1674s; 1605s; 1584m; 1522s 
2.11a H H H H H 3409m; 3325w; 3204w 2182m 1689s; 1649m; 1609m; 1579s 
2.11b H H Br CH3 H 3461w; 3320w 2193m 1668s; 1649m; 1602m; 1568s 
2.11c OCH3 H Br H H 3466w; 3354w 2176m 1669s; 1643m; 1599m; 1575m 
2.11d OCH3 H Br Cl H 3453w; 3320w 2175w 1657s; 1599s 
2.11e OCH3 H Br H OCH3 3489; 3359 2180m 1678s; 1649s; 1607m; 1595m; 1576w 
2.11f H H Cl CH3 H 3467m; 3319w 2193m 1669s; 1649s; 1603m; 1572s 
2.11g H H Br H OCH3 3463w; 3321w 2193m 1671s; 1652s; 1599m; 1580m 
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1H NMR Spectroscopy 
 Regarding to Tables 11 and 13, we note the presence of the amino group (-NH2) by a 
singlet in the spectra of both ĐoŵpouŶds ǀaƌǇiŶg fƌoŵ δ ϳ.ϰϳ to ϳ.ϲϯ ppŵ aŶd δ 6.82 to 7.03 
ppm for chromenes 2.10 and 2.11, respectively. 
 The -CH2 hydrogens appear as a multiplet between δ 3.13 to 3.20 ppm and δ 3.35 to 3.49 
ppm for chromenes 2.10 and 2.11, respectively. The hydrogen of C4 appears always as a doublet 
of doublets and varies from δ 4.24 to 4.29 ppm for compounds 2.10 and as a triplet and varies 
from δ 4.04 to 4.10 ppm for compounds 2.11. This difference in the multiplicity and chemical 
shift of the signal seems to be due to the presence of a carbonyl group or a cyano group in C3, 
affecting the dihedral angle with the neighboring methylene group.  
 As we can see, the chemical shift of the many substituent groups do not significantly 
vary in the same group of compounds or within the two-different group of synthetized 
chromenes. All 2.10 and 2.11 compounds present chemical shift variations respecting the 
standard. 
 
 
13C NMR Spectroscopy 
 According to Tables 12 and 14, the chemical shift of the carbonyl group (C=O) varies 
fƌoŵ δ ϭϵϳ.ϰϲ to ϭϵϴ.ϰϯ ppŵ for compounds 2.10 aŶd fƌoŵ δ ϭϵϲ.ϳϴ to ϭϵϳ.ϵϰ ppŵ for 
compounds 2.11, as is expected for the carbonyl group of ketones. 
 The signal for carbons CH2 and C4 vary between δ ϰϳ.ϯϰ to 48.09 ppm and δ 30.51 to 
38.18 ppm for compounds 2.10, and from δ 45.61 to 46.90 ppm and from δ 30.74 to 31.09 ppm 
for compounds 2.11. 
 The assignments were confirmed by the correlation spectra between 1H and 13C NMR 
for all the compounds. From the fixed and characteristic chemical shifts of CH2 and C4H, it was 
possible to confirm the identity of many other carbons on the purposed molecules. As it can be 
2.11h F H F H H 3473w; 3325w 2195m 1686s; 1656s; 1619m; 1596s 
2.11i OCH3 H Br CH3 H 3355w 2191s 1675s; 1605s; 1574m 
2.11j H H Br Br H 3463w; 3320w 2193m 1677s; 1650s; 1600m; 1568s 
2.11k OCH3 H Br Br H 3485m; 3355w 2176s 1679s; 1646s; 1607m; 1579m 
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seen by Figure 17, by CH2, it was possible to identify the carbon of the carbonyl group and, even 
C4H. It was also possible to recognize the 3-bond interactions for the two protons of CH2 with 
carbon C4a and C3. For proton C4H, many interactions were found to be preponderant to the 
correct identification of the empiric molecular structure. For 3-bond interactions were identified 
the carbon of the carbonyl group, C5, C8a, C2 and the carbon of EWG. At two bonds, a weak 
interaction was observed with carbon C3 as well as the carbon of CH2 and C4a. 
 
 
Figure 17. Interaction by bidimensional correlation of CH2 and C4H with the vicinity, for compounds 2.10 and 2.11. 
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Table 11. Spectroscopic data of 1H NMR (400 MHz, DMSO-d6) for 4H-chromenes 2.10. 
 
 
 
 
Comp R1 R2 
 
NH2 CH2 C4H Ar1-H (Ring A) Ar'-H (Ring C) 
2.10a 8-OCH3 ϰ’-Cl 
3.50 (s, 
3H, -
OCH3) 
7.62 (s, 
2H) 
3.13 (m, 
2H) 
4.27 (dd, J=4.8, 
2.4Hz, 1H) 
3.78 (s, 3H, -OCH3), 6.80 (dd, J=7.6, 1.2Hz, 1H, 
H5), 6.97 (t, J= 8.0Hz, 1H, H6), 6.90 (dd, J=8.0, 
1.6Hz, 1H, H7)  
7.59 (m, 1H, Hϰ’), 7.53 (dd, J=6.4, 2.0Hz, 2H, 
HϮ’+Hϲ’), 7.86 (dd, J=6.8, 2.0Hz, 2H, Hϯ’+ Hϱ’) 
2.10b 6-Br; H 
3.51 (s, 
3H, -
OCH3) 
7.47 (s, 
2H) 
3.17 (m, 
2H) 
4.29 (dd, J=4.8, 
2.4Hz, 1H) 
7.47 (dd, J=7.6, 1.2Hz, 1H, H5), 6.95 (d, J= 
8.8Hz, 1H, H8), 7.35 (dd, J=8.8, 2.4Hz, 1H, H7) 
7.48 (dd, J=6.4, 2.0Hz, 2H, Hϯ’+ Hϱ’), 7.88 (dd, 
J=8.0, 0.8Hz, 2H, HϮ’+Hϲ’)  
2.10c 
6-Br; 8-
OCH3 
ϯ’-OCH3 
3.52 (s, 
3H, -
OCH3) 
7.63 (s, 
2H) 
3.18 (m, 
2H) 
4.25 (dd, J=6.8, 
4.8Hz, 1H) 
3.81 (s, 3H, -OCH3), 7.00 (d, J=2.0, 1H, H5), 
7.08 (d, J= 2.0Hz, 1H, H7) 
3.79 (s, 3H, -OCH3), 7.37 (t, J=1.6Hz, 1H, HϮ’), 
7.16 (dd, J=8.0, 2.0Hz, 1H, Hϰ’), 7.38 (t, 
J=8.0Hz, 1H, Hϱ’), 7.44 (d, J=7.6Hz, 2H, Hϲ’) 
2.10d 6-Br ϰ’-Cl 
3.50 (s, 
3H, -
OCH3) 
7.59 (s, 
2H) 
3.16 (m, 
2H) 
4.27 (dd, J=4.8, 
2.4Hz, 1H) 
7.49 (d, J=2.4Hz, 1H, H5), 7.36 (dd, J= 8.8, 
2.4Hz, 1H, H7), 7.35 (d, J=8.4Hz, 1H, H8) 
7.88 (dd, J=11.2, 2.4Hz, 2H, HϮ’+Hϲ’), 7.54 (dd, 
J=6.4, 1.6Hz, 2H, Hϯ’+ Hϱ’) 
2.10e 
6-Br; 8-
OCH3 
H 
3.49 (s, 
3H, -
OCH3) 
7.62 (s, 
2H) 
3.13 (m, 
2H) 
4.24 (dd, J=4.8, 
2.0Hz, 1H) 
3.81 (s, 3H, -OCH3), 7.03 (d, J=2.0, 1H, H5), 
7.08 (d, J= 2.0Hz, 1H, H7) 
7.53 (dd, J=8.4, 1.6Hz, 2H, Hϯ’+ Hϱ’), 7.86 (dd, 
J=6.8, 2.0Hz, 2H, HϮ’+Hϲ’) 
2.10f 6-Cl H 
3.51 (s, 
3H, -
OCH3) 
7.57 (s, 
2H) 
3.20 (m, 
2H) 
4.29 (dd, J=6.8, 
4.4Hz, 1H) 
7.35 (d, J=2.8, 1H, H5), 7.23 (dd, J=8.8, 2.4Hz, 
1H, H7), 7.00 (d, J= 8.8Hz, 1H, H8) 
7.59 (m, 1H, Hϰ’), 7.48 (t, J=7.2Hz, 2H, Hϯ’+ 
Hϱ’), 7.88 (dd, J=8.0, 0.8Hz, 2H, HϮ’+Hϲ’) 
2.10g 6-Br ϰ’-Br 
3.50 (s, 
3H, -
OCH3) 
7.56 (s, 
2H) 
3.16 (m, 
2H) 
4.27 (dd, J=6.8, 
5.2Hz, 1H) 
7.48 (d, J=2.4, 1H, H5), 7.36 (dd, J=8.8 2.4Hz, 
1H, H7), 6.96 (d, J= 8.4Hz, 1H, H8) 
7.68 (dd, J=6.8, 2.0Hz, 2H, Hϯ’+ Hϱ’), 7.79 (dd, 
J=6.4, 2.0Hz, 2H, HϮ’+Hϲ’) 
2.10h 
6-Br; 8-
OCH3 
ϰ’-Br 
3.49 (s, 
3H, -
OCH3) 
7.63 (s, 
2H) 
3.15 (m, 
2H) 
4.24 (dd, J=6.4, 
4.8Hz, 1H) 
3.49 (s, 3H, -OCH3), 7.03 (d, J=2.0, 1H, H5), 
7.08 (d, J= 2.0Hz, 1H, H7) 
7.67 (dd, J=8.4, 1.6Hz, 2H, Hϯ’+ Hϱ’), 7.77 (dd, 
J=5.2, 1.6Hz, 2H, HϮ’+Hϲ’) 
Chapter II – Chemical Synthesis 
 
42 
 
 
Table 12. Spectroscopic data of 13C NMR (100 MHz, DMSO-d6) for 4H-chromenes 2.10. 
 
 
 
 
 
Comp R
1 R2 
 
C9 C=O CH2 C4H Ar1-C (Ring A) Ar-C (Ring B) Ar'-H (Ring C) 
2.10a 8-OCH3 ϰ’-Cl 50.31 168.23 197.45 48.09 38.18 
55.59 (-OCH3), 126.88 (C4a), 
119.57 (C5), 124.04 (C6), 110.61 
(C7), 146.88 (C8), 138.78 (C8a) 
161.94 (C2), 74.30 (C3) 
137.89 (Cϭ’), 129.88 
(CϮ’+Cϲ’), 128.88 (Cϯ’+Cϱ’), 
135.34 (Cϰ’) 
2.10b 6-Br; H 50.37 168.08 198.40 47.34 30.51 
128.67 (C4a), 130.95 (C5), 
115.58 (C6), 130.39 (C7), 117.77 
(C8), 148.93 (C8a) 
161.62 (C2), 73.94 (C3) 
136.67 (Cϭ’), 127.94 
(CϮ’+Cϲ’), 128.60 (Cϯ’+Cϱ’), 
133.10 (Cϰ’) 
2.10c 
6-Br; 8-
OCH3 
ϯ’-OCH3 50.41 168.12 198.21 47.94 30.60 
56.10 (-OCH3), 128.71 (C4a), 
122.06 (C5), 115.36 (C6), 113.67 
(C7), 147.76 (C8), 138.29 (C8a) 
161.55 (C2), 73.98 (C3) 
55.25 (-OCH3), 138.14 (Cϭ’), 
112.25 (CϮ’), 120.46 (Cϲ’), 
129.73 (Cϱ’), 119.27 (Cϰ’) 
2.10d 4-Br ϰ’-Cl 50.38 168.05 197.48 47.36 30.65 
128.70 (C4a), 130.98 (C5), 
128.75 (C6), 130.46 (C7), 117.80 
(C8), 148.93 (C8a) 
161.63 (C2), 73.82 (C3) 
135.36 (Cϭ’), 129.90 
(CϮ’+Cϲ’), 128.70 (Cϯ’+Cϱ’), 
138.03 (Cϰ’) 
2.10e 
6-Br; 8-
OCH3 
H 50.38 168.07 197.46 47.45 30.74 
56.19 (-OCH3), 128.67 (C4a), 
122.08 (C5), 115.44 (C6), 113.72 
(C7), 147.77 (C8), 138.28 (C8a) 
161.56 (C2), 73.84 (C3) 
137.98 (Cϭ’), 129.87 
(CϮ’+Cϲ’), 128.67 (Cϯ’+Cϱ’), 
135.38 (Cϰ’) 
2.10f 6-Cl H 50.39 168.12 198.43 47.33 30.62 
128.24 (C4a), 128.07 (C5), 
127.53 (C6), 127.65 (C7), 117.40 
(C8), 148.49 (C8a) 
161.69 (C2), 73.92 (C3) 
136.68 (Cϭ’), 127.96 
(CϮ’+Cϲ’), 128.63 (Cϯ’+Cϱ’), 
133.13 (Cϰ’) 
2.10g 6-Br ϰ’-Br 50.37 168.03 197.68 47.33 30.62 
128.52 (C4a), 130.97 (C5), 
115.63 (C6), 130.45 (C7), 117.79 
(C8), 148.92 (C8a) 
161.61 (C2), 73.80 (C3) 
135.66 (Cϭ’), 130.00 
(CϮ’+Cϲ’), 131.65 (Cϯ’+Cϱ’), 
127.22 (Cϰ’) 
2.10h 
6-Br; 8-
OCH3 
ϰ’-Br 50.36 168.05 197.65 47.43 30.71 
56.11 (-OCH3), 128.62 (C4a), 
122.06 (C5), 115.43 (C6), 113.71 
(C7), 147.76 (C8), 138.27 (C8a) 
161.54 (C2), 73.82 (C3) 
135.69 (Cϭ’), 129.97 
(CϮ’+Cϲ’), 131.61 (Cϯ’+Cϱ’), 
127.16 (Cϰ’) 
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Table 13. Spectroscopic data of 1H NMR (400 MHz, DMSO-d6) for 4H-chromenes 2.11. 
 
 
 
 
Comp R1 R2 NH2 CH2 C4H Ar1-H (Ring A) Ar'-H (Ring C) 
2.11a H H 
6.82 (s, 
2H) 
3.36 (m, 
2H) 
4.10 (t, 
J=5.6Hz, 1H) 
7.23 (m, 2H, H5+H6), 7.05 (td, J=7.2, 1.2Hz, 1H, 
H7) (6.98 (dd, J= 8.0, 0.8Hz, 1H, H8) 
7.60 (tt, J=14.8, 7.6, 1.2Hz, 1H, H4’), 7.47 (t, 
J=8.0Hz, 2H, Hϯ’+Hϱ’), 7.90 (dd, J=8.4, 1.2Hz, 
2H, HϮ’+Hϲ’) 
2.11b 6-Br ϰ’-CH3 6.89 (s, 
2H) 
3.43 (m, 
2H) 
4.08 (t, 
J=5.6Hz, 1H) 
7.23 (dd, J=2.4, 0.4Hz, 1H, H5), 7.38 (dd, J=8.8, 
2.4Hz, 1H, H7), 6.94 (dd, J= 8.8Hz, 1H, H8) 
2.35 (s, 3H, -CH3), 7.28 (d, J=8.0Hz, 2H, Hϯ’+Hϱ’), 
7.81 (dd, J=6.4, 1.6Hz, 2H, HϮ’+Hϲ’) 
2.11c 
6-Br; 8-
OCH3 
H 
6.90 (s, 
2H) 
3.39 (m, 
2H) 
4.06 (t, 
J=5.2Hz, 1H) 
3.81 (s, 3H, -OCH3), 7.10 (d, J=2.0Hz, 1H, H5), 
7.05 (d, J=1.6Hz, 1H, H7) 
7.61 (tt, J=7.6, 1.2Hz, 1H, Hϰ’), 7.48 (t, J=8.0Hz, 
2H, Hϯ’+Hϱ’), 7.91 (d, J=4.8Hz, 2H, HϮ’+Hϲ’) 
2.11d 
6-Br; 8-
OCH3 
ϰ’-Cl 6.91 (s, 
2H) 
3.38 (m, 
2H) 
4.05 (t, 
J=5.6Hz, 1H) 
3.81 (s, 3H, -OCH3), 7.06 (d, J=2.4Hz, 1H, H5), 
7.10 (d, J=2.4Hz, 1H, H7) 
7.54 (d, J=8.4Hz, 2H, Hϯ’+Hϱ’), 7.91 (d, J=8.4Hz, 
2H, HϮ’+Hϲ’) 
2.11e 
6-Br; 8-
OCH3 
ϯ’- OCH3 6.91 (s, 
2H) 
3.41 (m, 
2H) 
4.04 (t, 
J=5.2Hz, 1H) 
3.81 (s, 3H, -OCH3), 7.05 (d, J=2.0Hz, 1H, H5), 
7.10 (d, J=2.0Hz, 1H, H7) 
3.79 (s, 3H, -OCH3), 7.37 (t, J=2.4Hz, 1H, HϮ’), 
7.49 (dt, J=8.0, 1.2Hz, 1H, Hϰ’), 7.39 (d, J=8.0Hz, 
1H, Hϱ’), 7.18 (dd, J=8.4, 1.2Hz, 1H, Hϲ’) 
2.11f 6-Cl ϰ’-CH3 6.89 (s, 
2H) 
3.39 (m, 
2H) 
4.08 (t, 
J=5.6Hz, 1H) 
7.37 (d, J=2.4Hz, 1H, H5), 7.24 (dd, J=8.4, 
2.4Hz, 1H, H7), 7.00 (d, J= 8.8Hz, 1H, H8) 
2.35 (s, 3H, -CH3), 7.30 (d, J=8.0Hz, 2H, Hϯ’+Hϱ’), 
7.82 (d, J=8.0Hz, 2H, HϮ’+Hϲ’) 
2.11g 6-Br ϯ’- OCH3 6.89 (s, 
2H) 
3.44 (m, 
2H) 
4.08 (t, 
J=5.2Hz, 1H) 
7.49 (m, 1H, H5), 7.36 (dd, J=7.2, 2.8Hz, 1H, 
H7), 6.94 (d, J= 8.8Hz, 1H, H8) 
3.79 (s, 3H, -OCH3), 7.38 (t, J=2.4Hz, 1H, HϮ’), 
7.18 (ddd, J=8.0, 2.4, 0.8Hz, 1H, Hϰ’), 7.42 (d, 
J=8.0Hz, 1H, Hϱ’), 7.50 (m, 1H, Hϲ’) 
2.11h 6,8-F H 
7.03 (s, 
2H) 
3.49 (m, 
2H) 
4.11 (t, 
J=5.2Hz, 1H) 
7.07 (dt, J=9.2, 4.4, 2.0Hz, 1H, H5), 7.25 (m, 
1H, H7) 
7.60 (tt, J=8.8, 6.8, 1.6Hz, 1H, H4’), 7.48 (t, 
J=8.0Hz, 2H, Hϯ’+Hϱ’), 7.92 (dd, J=8.4, 1.2Hz, 
2H, HϮ’+Hϲ’) 
2.11i 
6-Br; 8-
OCH3 
ϰ’-CH3 6.89 (s, 
2H) 
3.35 (m, 
2H) 
4.04 (t, 
J=5.2Hz, 1H) 
3.81 (s, 3H, -OCH3), 7.04 (d, J=2.0Hz, 1H, H5), 
7.09 (d, J=2.4Hz, 1H, H7) 
2.35 (s, 3H, -CH3), 7.28 (d, J=8.0Hz, 2H, Hϯ’+Hϱ’), 
7.81 (d, J=8.0Hz, 2H, HϮ’+Hϲ’) 
2.11j 6-Br ϰ’-Br 6.90 (s, 
2H) 
3.45 (m, 
2H) 
4.08 (t, 
J=5.6Hz, 1H) 
7.52 (d, J=2.4Hz, 1H, H5), 7.38 (dd, J=8.8, 
2.4Hz, 1H, H7), 6.92 (d, J= 8.4Hz, 1H, H8) 
7.70 (d, J=8.8Hz, 2H, Hϯ’+Hϱ’), 7.84 (d, J=8.8Hz, 
2H, HϮ’+Hϲ’) 
2.11k 
6-Br; 8-
OCH3 
ϰ’-Br 6.91 (s, 
2H) 
3.37 (m, 
2H) 
4.05 (t, 
J=5.2Hz, 1H) 
3.81 (s, 3H, -OCH3), 7.06 (d, J=2.0Hz, 1H, H5), 
7.10 (d, J=2.4Hz, 1H, H7) 
7.70 (dd, J=6.8, 2.0Hz, 2H, Hϯ’+Hϱ’), 7.82 (dd, 
J=6.8, 2.0Hz, 2H, HϮ’+Hϲ’) 
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Table 14. Spectroscopic data of 13C NMR (100 MHz, DMSO-d6) for 4H-chromenes 2.11. 
Comp R1 R2 C≡N C=O CH2 C4H Ar1-C (Ring A) Ar-C (Ring B) Ar'-H (Ring C) 
2.11a H H 120.64 197.94 46.90 31.09 
123.92 (C4a), 128.11 (C5), 128.10 (C6), 
124.54 (C7), 115.94 (C8), 149.35 (C8a) 
161.64 (C2), 54.18 (C3) 
136.74 (Cϭ’), 128.08 (CϮ’+Cϲ’), 
128.76 (Cϯ’+Cϱ’), 133.34 (Cϰ’) 
2.11b 6-Br ϰ’-CH3 120.25 197.14 46.06 30.74 126.52 (C4a), 130.56 (C5), 115.82 (C6), 
130.65 (C7), 118.03 (C8), 148.67 (C8a) 
161.23 (C2), 53.80 (C3) 
21.12 (-CH3), 134.18 (Cϭ’), 
128.11 (CϮ’+Cϲ’), 129.18 
(Cϯ’+Cϱ’), 143.64 (Cϰ’) 
2.11c 
6-Br; 8-
OCH3 
H 120.26 197.65 46.27 30.88 
56.15 (-OCH3), 126.57 (C4a), 113.89 
(C5), 115.62 (C6), 121.62 (C7), 147.88 
(C8), 138.18 (C8a) 
161.19 (C2), 53.82 (C3) 
136.61 (Cϭ’), 127.99 (CϮ’+Cϲ’), 
128.65 (Cϯ’+Cϱ’), 133.26 (Cϰ’) 
2.11d 
6-Br; 8-
OCH3 
ϰ’-Cl 120.20 196.78 46.31 30.95 
56.13 (-OCH3), 126.40 (C4a), 121.61 
(C5), 115.63 (C6), 113.89 (C7), 147.85 
(C8), 138.15 (C8a) 
161.19 (C2), 53.65 (C3) 
135.26 (Cϭ’), 129.92 (CϮ’+Cϲ’), 
128.70 (Cϯ’+Cϱ’), 138.15 (Cϰ’) 
2.11e 
6-Br; 8-
OCH3 
ϯ’- OCH3 120.48 197.48 46.30 30.92 
56.14 (-OCH3), 126.52 (C4a), 121.61 
(C5), 115.59 (C6), 113.87 (C7), 147.86 
(C8), 138.18 (C8a) 
161.18 (C2), 53.77 (C3) 
55.28 (-OCH3), 138.04 (Cϭ’), 
112.23 (CϮ’), 159.34 (Cϯ’), 
120.48 (Cϰ’), 129.78 (Cϱ’), 
119.53 (Cϲ’) 
2.11f 6-Cl ϰ’-CH3 120.25 197.13 46.03 30.81 126.08 (C4a), 127.68 (C5), 127.87 (C6), 
127.76 (C7), 117.64 (C8), 148.20 (C8a) 
161.26 (C2), 53.74 (C3) 
21.11 (-CH3), 134.64 (Cϭ’), 
128.11 (CϮ’+Cϲ’), 129.18 
(Cϯ’+Cϱ’), 143.64 (Cϰ’) 
2.11g 6-Br ϯ’- OCH3 120.30 197.52 46.18 30.75 126.41 (C4a), 130.58 (C5), 115.83 (C6), 
130.68 (C7), 118.03 (C8), 148.71 (C8a) 
161.25 (C2), 53.73 (C3) 
55.31 (-OCH3), 138.04 (Cϭ’), 
112.27 (CϮ’), 159.36 (Cϯ’), 
119.55 (Cϰ’), 129.81 (Cϱ’), 
120.51 (Cϲ’) 
2.11h 6,8-F H 120.02 197.58 45.61 30.96 
127.63 (d, J=9.0Hz, C4a), 109.70 (dd, 
J=24.0, 3.0Hz, C5), 149.25 (dd, 
J=248.0, 14.0Hz, C6), 103.04 (dd, 
J=27.0, 21.0Hz, C7), 157.13 (dd, 
160.84 (C2), 53.69 (C3) 
136.53 (Cϭ’), 127.98 (CϮ’+Cϲ’), 
128.68 (Cϯ’+Cϱ’), 133.35 (Cϰ’) 
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J=240.0, 11.0Hz, C8), 134.44 (dd, 
J=11.0, 4.0Hz, C8a) 
2.11i 
6-Br; 8-
OCH3 
ϰ’-CH3 120.25 197.13 46.19 30.91 
56.15 (-OCH3), 126.65 (C4a), 121.60 
(C5), 115.60 (C6), 113.87 (C7), 147.88 
(C8), 138.15 (C8a) 
161.17 (C2), 53.85 (C3) 
21.12 (-CH3), 134.19 (Cϭ’), 
128.11 (CϮ’+Cϲ’), 129.18 
(Cϯ’+Cϱ’), 143.62 (Cϰ’) 
2.11j 6-Br ϰ’-Br 120.22 197.01 46.20 30.76 126.30 (C4a), 130.61 (C5), 115.86 (C6), 
130.72 (C7), 118.04 (C8), 148.67 (C8a) 
161.26 (C2), 53.62 (C3) 
135.58 (Cϭ’), 130.05 (CϮ’+Cϲ’), 
131.69 (Cϯ’+Cϱ’), 127.41 (Cϰ’) 
2.11k 
6-Br; 8-
OCH3 
ϰ’-Br 120.21 197.02 46.33 30.97 
56.16 (-OCH3), 126.43 (C4a), 121.63 
(C5), 115.65 (C6), 113.91 (C7), 147.87 
(C8), 138.17 (C8a) 
161.21 (C2), 56.16 (C3) 
135.60 (Cϭ’), 130.04 (CϮ’+Cϲ’), 
131.67 (Cϯ’+Cϱ’), 127.28 (Cϰ’) 
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1. IŶitial ĐoŵpouŶd viaďilitǇ sĐreeŶiŶg 
All the pure compounds synthetized and described in Experimental Section (Chapter 6) 
were tested for their biological activity. However, a series of chromenes, previously prepared in 
the research group by the PhD student Tatiana Dias [147] (Figure 18), was also included in this 
screening to assess if besides the substitution pattern, also the molecular scaffold could have 
any influence in the mode of action of the compounds. Therefore, a range of 51 compounds was 
evaluated for their anticancer properties by SRB assay. The first screening was performed on the 
Luminal-A subtype breast cancer cell line, MCF-7.  
 
 
Figure 18. Series of previously synthetized chromenes for first screening with MCF-7 cell line. 
 
Cells were treated with two different concentrations (10 and 30 µM) of all the 51 
compounds and evaluated for cell viability using the SRB assay in which total viable protein was 
quantified through total cell biomass in adherent cells. These concentrations were chosen based 
on previous results obtain on the research group [138]. After 72 hours of treatment, the SRB 
incorporated in viable cells was measured and the percentage of cell survival was calculated 
(Table 15). This first screening aimed to select a range of compounds that presented promising 
anticancer activity and, hereafter, would be evaluated against other cancer cells, HS578t (basal-
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like breast cancer cell line), and assess their cytotoxicity in the non-neoplastic breast MCF-10 
cell line (normal breast cell model).  
 
Table 15. Cell viability for MCF-7 cell line after 72 hours of treatment with two compound concentrations (10 and 30 
µM).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 As we can see by the analysis of structure-activity, generally compounds with 
halogenated substituents presented better anticancer activity when compared to molecules 
substituted with methoxyl (-OCH3) and methyl (-CH3) groups. However, within the group of 
halogens, bromine (-Br) presented enhanced activity comparing with chlorine (-Cl) and, even 
more, for fluorine (-F). The size of the halogen atom decreases in that equal order, but also the 
polarizability, a measure of the dynamical response of the electron cloud of the atom to the 
effect of a nearby external fields [138]. It was already reported in the literature that ϰ′-
bromoflavonol presents enhanced activity in a leukemia cell line comparing with other halogen 
Comp 
Cell viability (%)  
Comp 
Cell viability (%) 
10 µM 30 µM  10 µM 30 µM 
2.3a 67.0 28.1  2.11c 99.1 36.7 
2.3b 53.3 28.0  2.11d 49.6 33.3 
2.3c 77.3 63.1  2.11e 55.9 33.9 
2.3d 38.2 26.3  2.11f 85.5 49.0 
2.3e 26.9 28.3  2.11g 51.2 34.4 
2.3f 109.9 37.6  2.11h 99.6 76.9 
2.3g 36.8 27.7  2.11i 115.8 52.8 
2.3h 96.8 61.5  2.11j 47.2 34.2 
2.3i 28.7 28.3  2.11k 39.7 33.1 
2.3j 86.9 29.3  2.11l 102.0 58.4 
2.3k 27.3 31.8  2.11m 87.1 75.3 
2.3l 33.9 35.3  2.12a 111.2 106.3 
2.3m 64.6 48.3  2.12b 83.7 73.3 
2.3n 60.4 34.0  2.13a 97.3 81.5 
2.3o 71.9 32.1  2.13b 119 102.7 
2.10a 89.8 63.8  2.13c 88.5 52.9 
2.10b 106.7 41.3  2.13d 91.1 62.7 
2.10c 142.2 94.9  2.14 56.0 41.5 
2.10d 67.6 32.4  2.15a 122.2 123.4 
2.10e 80.3 33.8  2.15b 90.7 65.3 
2.10f 87.2 44.2  2.15c 109.3 96.3 
2.10g 72.5 34.8  2.15d 113.9 97.9 
2.10h 50.2 31.9  2.15e 59.2 48.8 
2.10i 68.3 40.3  2.15f 81.9 60.94 
2.11a 82.7 78.6  2.15g 117.5 106.2 
2.11b 69.0 32.3     
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substituents and even the number of methoxy groups (-OCH3) introduced in the molecular 
pattern [148]. 
In compounds 2.3k and 2.3n, assessing the role of hydroxyl group, when present, seems 
to be determinant in the inhibition of cell viability. Mizuno et al. described that chalcones with 
electron-withdrawing groups in meta position of the benzene ring, as halogens and hydroxyl, 
when tested against colon carcinoma cells (HT-29) had the highest inhibitory activities [149]. 
Finally, comparing the general activity of chalcones with the respective chromenes, it 
appears that both type of molecules have promising anticancer activity. In the literature, both 
molecules have already been described as anticancer agents with diverse ways of action in MCF-
7 cell line, as already described in Section I (Introduction) [74,101,110]. 
 From this first screening, it was possible to select a range of 22 compounds with more 
interesting and promising activity from their low cell survival rates for the tested cancer cell line 
MCF-7. Consequently, treatment of another breast carcinoma cell line (HS578t) was preformed 
to assess if the subtype of breast cancer could have a different response to the many 
compounds, probably attending to the differential receptor expression. Cytotoxicity was also 
evaluated for MCF-10 cell line aiming to determine if the promising molecules for cancer could 
be also harmful for normal cells.  Since chemotherapy present important side effects, screening 
for cytotoxicity, could allow to manage the molecular scaffold attending to the reduction of the 
side effects.  
As performed for the initial screening, cells were treated with two different 
concentrations (10 and 30 µM) of the compounds for 72 hours, and cell viability was evaluated 
by total biomass using the SRB assay. Results for the two cell lines are summarized in Table 16.  
In general, HS578t cell line sensitivity to the 22 compounds was inferior than for MCF-7 
cells probably explained by the subtype of cancer including differential hormone receptor 
expression (Table 16). HS578t is a basal-like breast cancer subtype, with no known target, poor 
prognosis and less options of available treatments that present good response. Consequently, 
for 30 µM, many were the molecules that presented a significant reduction in cell viability in the 
range up to 50% with lower cytotoxicity for normal cells, making them interesting molecules to 
explore in the treatment of this subtype of breast cancer. 
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Table 16.  Cell viability for HS578t and MCF-10 cell lines after 72 hours of treatment at 10 and 30 µM. 
Comp 
Cell Viability (%) 
10 µM 30 µM 
HS578t MCF-10 HS578t MCF-10 
2.3a 46.9 105.8 34.4 40.7 
2.3b 53.8 60.3 35.2 47.8 
2.3c 74.2 69.8 33.5 47.0 
2.3e 38.5 55.8 33.8 66.3 
2.3f 96.5 114.1 37.4 41.4 
2.3g 66.3 70.5 33.5 51.1 
2.3h 84.6 64.2 155.3 147.9 
2.3i 63.5 124.1 32.8 47.6 
2.3j 105.9 101.9 35.7 48.0 
2.3k 55.8 46.7 32.4 49.4 
2.10e 63.0 90.2 40.9 47.8 
2.10g 90.0 94.8 39.9 43.2 
2.11b 88.8 46.3 133.0 33.5 
2.11c 100.4 154.9 45.9 45.9 
2.11d 90.7 90.7 36.8 41.6 
2.11e 46.1 83.3 32.3 46.3 
2.11f 92.3 154.9 41.8 53.3 
2.11g 71.5 37.9 101.1 43.7 
2.11i 92.4 144.3 53.8 128.5 
2.11j 67.6 93.8 32.6 43.6 
2.13c 73.3 98.9 44.9 78.2 
2.15e 67.2 112.1 69.8 106.1 
 
 For MCF-10 cells, the results were quite promising. Almost every compound assessed 
led to a 50% (or more) cell survival for the 30 µM concentration increasing the possibilities of 
treatment with this type of compounds due to low values of citotoxicity. 
 Combining all the results from this first screening, we limited the range of compounds 
to further assess the survival curves and determine the IC50 values. Hence, regarding the results 
of Tables 15 and 16 where we can find the cell viability for the two-tested concentrations (10 
and 30 µM) for each of the 22 compounds, it was possible to select chalcones 2.3 (b, e, g and i) 
and chromenes 2.11 (e, g and j). 
 
2. Survival Đurves aŶd ICϱ0 deterŵiŶatioŶ 
The IC50 for each cell line and compound was determined by SRB assay. Cells were 
treated with 7 different concentrations of compounds 2.3 (b, e, g and i) and 2.11 (e, g and j) 
from 60, 30, 10, 5, 1, 0.1 to 0.01 µM. 
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In general, more molecules with bromine (-Br) in ring A presented enhanced activity 
when compared to other substituents (Figure 19), as previously reported in the first screening 
results. These molecules were selected for IC50 determination, varying mostly the substituents 
in ring B. Results from the IC50 determination for the 3 cell lines are summarized in Table 17 and 
the survival curves are presented in Figure 20. 
 In general, the selected compounds maintained reduced cytotoxicity for MCF-10 cells. 
However, the minimal inhibitory concentration for some compounds (2.3b, 2.3k, 2.11g and 2.11j 
in Figure 20 and Table 17) when compared with IC50 values obtained for normal cells, 
demonstrated a very low therapeutic index (between 0.9 and 3). Therapeutic index (TI) was 
defined as the ratio between the concentration of therapeutic agent with desirable effect (IC50 
for MCF-7 or HS578t) and the amount that causes toxicity (IC50 for MCF10). Thus, these four 
compounds were excluded from the series since the major problem of these compounds is the 
low TI, turning them less suitable, probably leading to important side effects. However, to 
confirm these results some other normal models could be used as another non-neoplastic cell 
line. The low TI is also a problem present in some chemotherapy agents such as 5-FU, still 
currently used for treatment of basal-like breast cancer subtypes, that has a TI around 2.0-3.0 
µg/mL and presents important toxicity to the bone marrow and gastro-intestinal tract [149,150]. 
In order to increase the therapeutic index of anticancer drugs, cancer research must continue. 
 On the other hand, compounds 2.3e, 2.3g, 2.3i and 2.11e (Table 17) presented 
satisfactory TI as shown by the IC50 of the normal cell line MCF-10 comparing to the IC50 of both 
cancer cell lines. Regarding their molecular structure, three of these four compounds contain 
Figure 19.  Selected compound for IC50 determination in MCF-7, HS578t and MCF-10 cell lines. 
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bromine and, only one, chlorine. This fact might be justified by the different polarizabilities, as 
previously discussed. 
Figure 20. Effect of chalcones and chromenes on MCF-7, HS578t and MCF-10 cells for total cell biomass (72 hours of 
treatment). Results are expressed as mean ± SD. 
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Table 17.  IC50 values of the eight compounds selected for MCF-7, HS578t and MCF-10 cells. 
 
 
 
 
 
 
 
From this assay, only four compounds 2.3e, 2.3g, 2.3i and 2.11e proceeded to more 
specific tests such as cell migration capacity (wound healing assay), proliferation (BrdU 
incorporation), cell membrane integrity (trypan blue assay) and protein expression using 
Western Blotting. 
 
3. EffeĐt of seleĐted ĐoŵpouŶds oŶ Đell ŵigratioŶ  
Migration and invasion capacity of malignant cells are two of the main features involved 
in cancer progression and metastasis. To assess if cell migration was being affected, compounds 
with more promising anticancer power were tested by treating MCF-7 cells with respective ½IC50 
and IC50 during 48 hours for each compound described in Figure 21 and performing the wound-
healing assay. These concentrations were selected once they would kill half of the total cells 
within 72 hours of treatment however, sometimes, with ½ IC50, the migration is affected which 
would be advantageous since it would allow an anticancer effect with lower concentration of 
drug required. At the beginning and regular timepoints (12, 24 and 48 hours), images were 
captured as it can be seen in Figure 22 and the progression of the scratch closure for each 
compound is summarized in Figure 23. 
 IC50 (µM) 
Comp MCF-7 HS578t MCF-10 
2.3b 5.15 5.33 12.11 
2.3e 5.07 7.27 40.64 
2.3g 3.98 4.80 24.25 
2.3i 3.82 5.88 29.26 
2.3k 2.00 1.60 6.52 
2.11e 3.65 4.52 18.87 
2.11g 5.94 10.26 18.93 
2.11j 7.24 16.48 14.66 
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Figure 21. Selected compounds for cell migration assay in MCF-7 cells. 
 
 
Figure 22. Representative images of control (A) and effect of chalcones 2.3e (B), 2.3g (C) and 2.3i (D) and chromene 
2.11e (E) on MCF-7 cell migration (12, 24 and 48 hours of treatment with the respective IC50 of each compound) by 
wound healing assay. 
 
As shown in Figure 22, MCF-7 cells showed a satisfactory migratory capacity since the 
scratch significantly reduced when cells were not treated. In general, chromene 2.11e presented 
a much more promising inhibitory ability than the three chalcones tested (compounds 2.3e, 2.3g 
and 2.3i). Treatment with this compound for 48 hours was able to decrease the percentage of 
cell migration relative to control (0.5% DMSO) as shown in Figure 23 (around 50%). Several 
chromenes were already reported as being good anti-migratory agents against breast cancer cell 
lines tested through wound-healing assay [144,145]. Both apigenin and luteolin are naturally 
occurring chromenes with similar and simple structures as compound 2.11e. In the case of 
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apigenin, the inhibitory effect was reported as being caused by the downstream signaling 
blockage of PI3K/Akt pathway necessary for motility induced by HGF as well as adherence 
junction disassembly [153]. However, as it can be seen in Figure 22, the majority of the cells died 
by the treatment as it was not able to determine if the inhibitory power was due to loss of 
migratory ability or by cell death induction. Then, the capacity to induce cell death will be further 
assessed to examine if cells could be undergoing apoptosis. 
 
Figure 23. Effect of chalcones 2.3e (A), 2.3g (B) and 2.3i (C) and chromene 2.11e (D) on MCF-7 cell migration (12, 24 
and 48 hours of treatment) by the wound-healing assay. Results are presented as mean ± SD of three independent 
experiments. *p=0.01, **p=0.0022 ***p=0.0001, ****p<0.0001 compared to control (DMSO). 
 
Within chalcones, the cell migration was not significantly affected (Figure 23). In the 
literature, not many articles are found relating chalcones with inhibition of MCF-7 (or other 
breast cancer cell line) cell migration. According to results reported by Lin et al. non-substituted 
chalcones presented anti-migratory effect against AGS (human gastric adenocarcinoma) [154]. 
This compound, assessed by wound healing assay, inhibited around 67% cell migration after 24 
hours of treatment with 2 µg/mL. 
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4. EffeĐt of ĐhalĐoŶes aŶd ĐhroŵeŶes oŶ Đell proliferatioŶ  
In this experiment, the inhibitory influence on cell proliferation of the four best 
chalcones and chromenes was evaluated. MCF-7 cells were treated with IC50 and ½ IC50 values, 
for 24 and 48 hours. In this technique, the ability of BrdU incorporation during DNA synthesis is 
measured. Figure 24 summarizes the obtained results. 
 
 
Figure 24. Effect of chalcones 2.3e (A), 2.3g (B) and 2.3i (C) and chromene 2.11e (D) on MCF-7 cell proliferation after 
24 and 48 hours of treatment. Results are presented as mean ± SD of at least three independent experiments. 
**p<0.005, ****p<0.0001 compared to control (0.5% DMSO). 
  
 As shown the analysis of Figure 24, chalcones induced a significant decrease in cell 
proliferation, in a time dependent manner, for MCF-7 cells. In the group of chalcones, the 
highest effect was observed for compounds 2.3e and 2.3g with about 50% reduction in cell 
proliferation at 48 hours. A smaller effect was observed for compound 2.3i that only reduced 
cell proliferation in about 25% at the same timepoint. Recently, a series of synthesized 
chalcones, very similar to those tested in this assay, presented good activity as anti-proliferative 
agents against several cell lines, including MCF-7 [155]. One chalcone of this described range, 
substituted with a methoxy group, was described to inhibit significantly BrdU incorporation and, 
consequently, cell proliferation around 33% when compared to the control. Additionally, more 
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assays were performed to analyze the cell cycle profile of NCI-H460 cells treated with this 
compound. Cellular arrest was significantly observed for the G0/G1 phase, from 56.3 to 68.0%, 
accompanied with decrease of S phase cell arrest. 
On the other hand, chromene 2.11e did not affected cell proliferation maintaining 
similar rates comparing to the control (0.5% DMSO) (Figure 24). In literature, many studies 
involve chromenes as anticancer agents affecting cell proliferation [113,115,117,119,120]. In 
particular, two chromenes with a scaffold similar to compound 2.11e, were tested against H47D 
breast carcinoma, these compounds revealed a good inhibitory activity [146]. Attending at the 
molecular structures, compounds tested by Yin and co-workers were not substituted with an 
extra aryl group, keeping the structure quite simple and making possible the interaction of the 
ethoxy oxygen atom, forming an additional hydrogen bond with residues of Try867 and Asp964 
in the hydrophobic pocket observed by molecular docking. 
 
5. EffeĐt of seleĐted ĐoŵpouŶds oŶ ŵeŵďraŶe iŶtegritǇ 
Trypan blue gives a different approach of cell viability and we can assess how the viability 
of cells can be analyzed through the integrity of their membrane. Trypan blue is an assay used 
for survival purposes where viable and non-viable cells are counted through the ability to 
exclude dye. In this case, only adherent and viable cells were analyzed and taken into account. 
This procedure gave us a final idea of the IC50 effect on cell viability after three timepoints (24, 
48 and 72 hours. Results are summarized in Figure 25 where cells were exposed to treatment 
with the respective ¼ IC50, ½ IC50 and IC50 of each identified compound. 
The trypan blue exclusion assay allows a direct identification and enumeration of living 
(unstained) and dead (blue) cells in a certain population. For many years, trypan blue has been 
used to assess cell viability and survival, however as every technique, it presents drawbacks. In 
terms of the operator health, it is considered to be hazardous and must be handled with care 
and disposed of appropriately. Finally, when compared to fluorescent based detection 
approaches, multiple publications have observed that trypan blue viability counts presented 
discrepancies for samples that had lower than 70% viable cells [156]. 
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Figure 25. Membrane integrity of MCF-7 cell line for 24, 48 and 72 hours treated with the respective ¼IC50, ½IC50 and 
IC50 of chalcones 2.3e (A), 2.3g (B) and 2.3i (C) and chromene 2.11e (D). Results are presented as mean ± SD of at least 
three independent experiments. 
 
Every tested compound led to a reduction in cell viability and plasmatic membrane 
integrity of 50% or more after 48 hours of treatment. Chalcone 2.3e and chromene 2.11e led to 
the greatest reduction in viability of the four molecules, with a decrease of about 75% of 
membrane integrity for the 72 hours treatment with the respective IC50 concentration. These 
two compounds are dissimilar in their molecular scaffold however coincidentally, or not, both 
molecules have one halogen (-Br) and, at least, a methoxyl group (-OCH3) in their substitution 
pattern. On the other hand, compound 2.3g has chloride (-Cl) and methyl (-CH3) and 2.3i has 
two bromine (-Br). 
Overmeyer et al. reported in 2011 that a chalcone-like small molecule induced the 
accumulation of vacuoles in glioblastoma cells (U251 cell line resistant to temozolomide) and 
filled the cell, decreasing ATP and mitochondrial membrane potential damaging metabolic 
function. Ultimately, these alterations led to disruption of membrane integrity and rupture of 
cells [157]. It was described that it induces cytoplasmic vacuolization and, consequently, a non-
apoptotic cell death very similar to methuosis, a way of death triggered by modifications in the 
trafficking of clathrin-independent endosomes. 
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Recently, very similar 2.11e compounds were reported as being apoptotic inducers for 
diverse cell lines, including MCF-7 cells, through loss of cytoplasmic membrane integrity [158]. 
The evaluation of apoptosis-inducing ability was made by fluorescent dyes (acridine orange-
ethidium bromide) and DNA fragmentation. 
On the other hand, MCF-10 cells did not appear to have their membrane integrity 
affected by exposure to compounds 2.3e, 2.3g, 2.3i and 2.11e (Figure 26). Only after 72 hours, 
the aggregated cells seem to begin to respond to the treatment. This fact is important since 
cancer cells are affected already after 24 hours even at ½IC50, turning the treatment potentially 
harmless and non-cytotoxic to normal cells and effective for MCF-7 cancer cell line. 
 
 
Figure 26. Membrane integrity of MCF-10 cell line for 24, 48 and 72 hours treated with the respective ¼IC50, ½IC50 and 
IC50 of chalcones 2.3e (A), 2.3g (B) and 2.3i (C) and chromene 2.11e (D). Results are presented as mean ± SD of at least 
three independent experiments. 
 
6. EffeĐt oŶ proteiŶ eǆpressioŶ 
As previously described, chalcones and chromenes were reported, by several research 
groups as anticancer agents through pro-apoptotic mechanisms. Once tumor cells are highly 
adapted to different conditions due to their high ability of proliferate and escape apoptosis, 
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protein expression levels was evaluated. To assess which kind of protein expression could be 
involved in the toxicity induced by these compounds, two proteins involved in apoptotis (PARP 
and Casp-9) and a protein involved in cancer cell metabolism (CAIX) were tested for their 
expression. MCF-7 cells were incubated for 24 hours with IC50 values of compounds 2.3e, 2.3g, 
2.3i and 2.11e. 
Poly (ADP-ribose) polymerase (PARP) is activated by DNA damage as breaks in the DNA 
strands once it is involved in DNA repair mechanisms and, also, programmed cell death. When, 
cleaved by caspase family during cellular apoptosis, the peptide strand of 126kD is separated in 
two segments of 89kD and 24kD. For breast cancer treatment, many PARP inhibitors are 
currently in trials for the adjuvant, neoadjuvant, and metastatic settings [159]. 
Caspase-9 (casp-9) is considered an initiator caspase. The stress induction in JNK/SAPK 
has shown to activate a pro-enzyme of casp-9 through the release of cytochrome C from 
mitochondria and activation of the apoptosome [160]. In its full length, it has 47kD and, when 
activated, through cleavage, it can have two different segment lengths, 35kD and/or 37kD. Once 
activated, it cleaves procaspase-3/7 which will cleave PARP and other several cellular targets. 
Carbonic anhydrase IX (CAIX) is a cell membrane-associated protein involved in glycolytic 
metabolism and hypoxia cellular biomarker [161]. This specific carbonic anhydrase is tumor-
associated and overexpressed in many cancer types, including breast cancer. It is believed that 
it might be involved in cell proliferation. This protein expression was chosen to be evaluated due 
to a recent emerging hallmark of cancer cells, the ability to alter, or reprogram, cellular 
metabolism. 
As it can be seen in Figure 27, CAIX expression seems to be enhanced in cancer cells 
treated with the synthetized compounds, as it was predictable by the glycolytic tumor origin of 
MCF-7 cells. Comparing to control, this expression seems to be increased which may lead to 
believe that despite the initial adaptive and usual glycolytic capacity of cancer cells, these might 
be trying to consume more energy possibly to resist treatment. Recently, a docking study was 
performed to evaluate the possible interactions of the active site of CAIX with newly synthetized 
chromenes [162]. From the initial series of molecules, two compounds were found to be 
promising CAIX inhibitors. 
One the other hand, cell death associated with apoptosis only seems to be involved in 
cells treated with compound 2.11e. The expression of cleaved Casp-9 and cleaved PARP is 
enhanced with this chromene comparing with the other compounds, chalcones. Many 
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chromenes, both naturally occurring or synthetized, were previously reported as anticancer 
agents through apoptosis-inducers [112,139]. 
It is important to note that besides the importance of this information, all the presented 
results are preliminary due to the lack of data pƌoǀided ďǇ the housekeepiŶg pƌoteiŶ ;β-tubulin) 
and will need to be repeated. 
 
Figure 27. Representative blot of effect of compounds 2.3e, 2.3g, 2.3i and 2.11e on MCF-7 cells - caspase-9, PARP and 
CAIX (24 hours treatment) by Western blot analysis. Similar blots were obtained in the two independent experiments. 
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Conclusions 
The search for novel and effective breast cancer treatments is increasing with the 
particular concern to reduce side effects. These advances improve the patients quality of life 
and higher survival rates. 
IŶ this Masteƌ’s thesis, a good number of novel compounds (chalcones and chromenes) 
were synthetized by eco-friendly methodologies, with good yield and high levels of purity. 
Synthetic chalcones and chromenes have demonstrated to be powerful anticancer 
agents through all the assays performed. Halogenated substituents presented more interesting 
capacities than methoxy or methyl groups when they were the only substituents in the 
molecular scaffold. Bromine atom was frequently the halogen most present in the bioactive 
molecules that proceeded to the final assays and showed to be promising candidates for further 
studies.  
Specifically, a chromene (Figure 28) has demonstrated to be involved in the inhibition of 
cell migration and, preliminary results, found that apoptotic-inducing could be the cause for cell 
death when treated with this molecule. 
 
Figure 28. Most promising chromene structure. 
 
Regarding to chalcones, these compounds also showed to be bioactive molecules by 
inhibiting cell proliferation and disrupting the membrane integrity. 
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Future work 
As it can be seen by Figure 28, modification of the substitution pattern could be further 
explored as the nature and position of the substituents on the aromatic rings is crucial for the 
biological activity one of the further works that can be done. Evaluate the citotoxicity of novel 
molecules and the possible influence of different substituents in ring C or the variation in the 
several available positions. Elemental analysis in also one of the many molecular 
characterization methods that can be performed in future studies to assess, once more, the 
purity of the synthetized chromenes and chalcones and confirm their empirical formula. 
Subsequently, the protein expression assay should be optimized and other several 
proteins could be assessed for their involvement in the anticancer activity of the tested 
compounds. It is also intended to understand which pathways might be affected by the 
treatment with these novel compounds. 
Additionally, once compounds were already tested in three different cell lines for in vitro 
assays and they do not mimic all real tumor conditions, for more interesting compounds in vivo 
studies should be performed in order to comprehend the way of action in more complex models. 
Finally, some molecular docking studies also could be performed to understand the 
possible interactions with active sites of different proteins and a way to improve the molecules 
by increasing the number of interactions with important amino acids. 
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1. EǆperiŵeŶtal proĐedures  
All chemicals, reagents and solvents for compounds synthesis were analytical grade, 
purchased from commercial sources and used without further purification, unless otherwise 
specified. Reactions were monitored by thin layer chromatography (TLC) using silica gel 60 plates 
purchased from Macherey-Nagel with a 0.2 mm and a fluorescence indicator. An UV chamber 
(CN-6 Vilber Lourmat) with a 254 nm lamp was used for revelation. Dry flash chromatography 
was performed with silica gel (particle size <0.063 mm) from MN Kieselgel 60 (230 ASTM). For 
reactions at high temperatures, a hot plate stirrer IKAMAG RCT was used, with magnetic stirring 
at 40 rpm and at different temperatures according to the specific procedure. For solvent 
evaporation, a Buchi RE 11 rotary evaporator was used with vacuum and variable bath 
temperature. 
NMR spectra were obtained in Bruker Avance III (at 400 MHz for 1H NMR and 100 MHz 
for 13C NMR), at 25ºC, with deuterated dimethylsulfoxide (DMSO-d6) as solvent. Chemical shifts 
were recorded in parts per million (ppm) using the residual solvent peak as an internal standard. 
IR spectra were recorded in FT-IR Bomem MB 104 using nujol mulls and NaCl cells. Melting points 
were determined in a Stuart SMP3 melting point apparatus and are uncorrected. Elemental 
analysis was performed on a LECO CHNS-932 instrument. 
 
Synthesis of 3,5-difluoro-2-hydroxybenzaldehyde 
This compound is commercially available but was synthetized in our laboratory 
according to established procedures. Hexamethylenetetramine (4.35 g; 31.05 mmol) 
was added to a colorless solution of 2,4-difluorophenol (1.98 mL; 2.109 g; 20.7 mmol) 
in TFA (14 mL; 21.2 g; 184.76 mmol). The reaction mixture was stirred at 40ºC for 15 
minutes, increasing the temperature to 80ºC and, after 1 hour, to 110ºC. After 18 hours, the orange 
mixture was cooled until to room temperature and a yellow solid precipitated by adding 91.6 mL of 
H2O. The product was filtered and washed with H2O leading to 3,5-difluoro-2-hydroxybenzaldehyde 
(2.114 g; 18.6 mmol; 89.9%). 
 
 
1.1. General procedure for the synthesis of chalcone 
derivatives 
Aqueous 3M NaOH was added to a solution of substituted salicylaldehyde and acetophenone in 
ethanol. The solution was stirred at an appropriate temperature leading to a red solution. The 
solution was neutralized with concentrated HCl (37%) leading to a yellow suspension, cooled to room 
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temperature and set in the ultrasound for a few minutes. A yellow solid was filtered and washed with 
ethanol and water leading to the α,β-unsaturated carbonyl compound. 
 
Synthesis of (E)-3-(2-hydroxy-3-methoxyphenyl)-1-phenylprop-2-en-1-one (2.3p) 
Following the general procedure, aqueous 3M NaOH  (10 mL) was added to 
a solution of 2-hydroxy-3-methoxybenzaldehyde (0.50g, 3.32 mmol) and 
acetophenone (355µL, 3.01 mmol) in ethanol (10 mL) leading immediately 
to a red solution that was stirred at room temperature overnight leading to 
a red suspension. The suspension was filtered under vacuum leading to a 
red solid, washed with cold ethanol and identified by IR and 1H NMR as (E)-3-(2-hydroxy-3-
methoxyphenyl)-1-phenylprop-2-en-1-one (0.88g, 3.2 mmol, 94.0%) (Tables 5 and 6). 
 
Synthesis of (E)-3-(2-hydroxyphenyl)-1-phenylprop-2-en-1-one (2.3o) 
Following the general procedure, aqueous 3M NaOH  (7 mL) was added to a 
solution of salicylaldehyde (260µL, 2.46 mmol) and acetophenone (310µL, 2.11 
mmol) in ethanol (7 mL) resulting in a red solution. After being stirred for 31 hours 
at room temperature, the solution was neutralized with concentrated HCl leading 
to a light yellow suspension. This suspension was cooled slightly above room 
temperature and was filtered tepid leading to a pale yellow pure product identified by IR, 1H and 13C 
NMR as (E)-3-(2-hydroxyphenyl)-1-phenylprop-2-en-1-one (0.24g, 1.19mmol, 48.4%) (Tables 5, 6 and 
7). 
 
Synthesis of (E)-3-(5-bromo-2-hydroxy-3-methoxyphenyl)-1-phenylprop-2-en-1-one (2.3a) 
Following the general procedure, aqueous 3M NaOH  (10 mL) was added to 
a solution of 5-bromo-2-hydroxy-3-methoxybenzaldehyde (0.50g, 2.16 
mmol) and acetophenone (230µL, 1.96 mmol) in ethanol (10 mL) leading 
immediately to a red solution that was stirred for 22 hours at 40ºC. Then, 
the reaction was neutralized at room temperature with concentrated HCl 
forming a yellow solid suspension that was cooled at 4ºC for 45 minutes. 
After that, the yellow solid was filtered, washed with water and identified by IR, 1H and 13C NMR as 
(E)-3-(5-bromo-2-hydroxy-3-methoxyphenyl)-1-phenylprop-2-en-1-one (0.72g, 2,16 mmol, 99.7%) 
(Tables 5, 6 and 7). 
 
Synthesis of (E)-3-(3,5-difluoro-2-hydroxyphenyl)-1-phenylprop-2-en-1-one (2.3f) 
Following the general procedure, aqueous 3M NaOH (5 mL) was added to a 
solution of 3,5-difluoro-2-hydroxybenzaldehyde (0.21g, 1.32 mmol) and 
acetophenone (180µL, 1.45 mmol) in ethanol (5 mL) leading immediately to a 
red solution that was stirred for 4 hours at room temperature. Then, the 
reaction was neutralized at room temperature with concentrated HCl leading 
to a pale yellow suspension that was cooled for 15 hours at -20ºC. After that, 
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a light yellow solid was filtered and identified by IR, 1H and 13C NMR as (E)-3-(3,5-difluoro-2-
hydroxyphenyl)-1-phenylprop-2-en-1-one (0.26g, 0.99 mmol, 75.0%) (Tables 5, 6 and 7). 
 
Synthesis of (E)-3-(5-bromo-2-hydroxy-3-methoxyphenyl)-1-(4-chlorophenyl)prop-2-en-1-one 
(2.3b) 
Following the general procedure, aqueous 3M NaOH (10 mL) was 
added to a solution of 5-bromo-2-hydroxy-3-methoxybenzaldehyde 
(0.52 g, 2.26 mmol) and 1-(4-chlorophenyl)ethanone (270µL, 2.05 
mmol) in ethanol (10 mL) leading to a red solution. This solution was 
stirred at 40ºC during 18 hours and 30 minutes and was then 
neutralized with concentrated HCl leading to a light brown suspension that was cooled at 4ºC for 45 
minutes. The light brown solid was filtered and identified by IR, 1H and 13C NMR as (E)-3-(5-bromo-
2-hydroxy-3-methoxyphenyl)-1-(4-chlorophenyl)prop-2-en-1-one (0.55g, 1.48 mmol, 65,6%) (Tables 
5, 6 and 7). 
 
Synthesis of (E)-3-(5-chloro-2-hydroxyphenyl)-1-(4-chlorophenyl)prop-2-en-1-one (2.3r) 
Following the general procedure, aqueous 3M NaOH (6 mL) was added to a 
solution of 5-chloro-2-hydroxybenzaldehyde (0.29g, 1.88mmol) and 1-(4-
chlorophenyl)ethanone (268µL, 2.07mmol) in ethanol (6 mL) leading 
immediately to a red solution stirred at room temperature for 6 hours. This 
solution was cooled to -20ºC for 17 hours and, finally, neutralized with 
concentrated HCl until pH±2 leading to a light yellow suspension that was 
kept at 4ºC for 45 minutes. The yellow solid was filtered and identified by IR, 1H and 13C NMR as (E)-
3-(5-chloro-2-hydroxyphenyl)-1-(4-chlorophenyl)prop-2-en-1-one (0.49g, 1.66mmol, 88.3%) (Table 
6). 
 
Synthesis of (E)-1-(4-chlorophenyl)-3-(2-hydroxy-5-methoxyphenyl)prop-2-en-1-one (2.3j) 
Following the general procedure, aqueous 3M NaOH (12 mL) was added 
to a solution of 2-hydroxy-4-methoxybenzaldehyde (0.68g, 4.44 mmol) 
and 1-(4-chlorophenyl)ethanone (765µL, 5.77 mmol) in ethanol (4mL) 
leading to a dark red solution. The solution was stirred at room 
temperature for 18 hours and was neutralized with concentrated HCl 
until pH±2 leading to a colorless solution with an orange precipitate. The solid was filtered and 
1H NMR analysis showed that (E)-1-(4-chlorophenyl)-3-(2-hydroxy-5-methoxyphenyl)prop-2-en-
1-one ǁas ĐoŶtaŵiŶated ǁith ϰ’-cloroacetophenone contamination in a 1:0.4 ratio. The solid 
was washed with strong stirring for 4 hours with 10 mL of distilled water and 3 mL of ethanol. 
The orange solid was filtered and by IR, 1H and 13C NMR confirmed that it was pure (E)-1-(4-
chlorophenyl)-3-(2-hydroxy-5-methoxyphenyl)prop-2-en-1-one (1.07g, 3.72mmol, 83.8%) 
(Tables 5, 6 and 7). 
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Synthesis of (E)-3-(5-bromo-2-hydroxyphenyl)-1-(3-methoxyphenyl)prop-2-en-1-one (2.3e) 
Following the general procedure, aqueous 3M NaOH (10 mL) was added to a 
solution of 5-bromo-2-hydroxybenzaldehyde (0.46g, 2.31 mmolͿ aŶd ϯ’-
methoxyacetophenone (350µL, 2.104 mmol) in ethanol (10 mL) leading to a red 
solution. After stirring for 23 hours at room temperature, the solution was 
neutralized with concentrated HCl leading to a dark yellow suspension. This 
suspension was filtered and the yellow solid was identified by IR, 1H and 13C NMR as (E)-3-(5-bromo-
2-hydroxyphenyl)-1-(3-methoxyphenyl)prop-2-en-1-one (0.63g, 1.89mmol, 81.8%) (Tables 5, 6 and 
7). 
 
Synthesis of (E)-3-(5-chloro-2-hydroxyphenyl)-1-(3-methoxyphenyl)prop-2-en-1-one (2.3d) 
Following the general procedure, aqueous 3M NaOH (10 mL) was added to a 
solution of 5-chloro-2-hydroxybenzaldehyde (0.39g, 2.10Ϭ ŵŵolͿ aŶd ϯ’-
methoxyacetophenone (378µL, 2.115 mmol) in ethanol (10mL) leading to a dark 
red solution. After stirring for 16 hours and 30 minutes at room temperature, the 
solution was neutralized with concentrated HCl until pH±3 resulting in an orange 
solution with a pale yellow precipitate. Then it was cooled for 2 hours at 4ºC and, 
finally, a pale yellow product was filtered and identified by, IR, 1H and 13C NMR, as (E)-3-(5-chloro-2-
hydroxyphenyl)-1-(3-methoxyphenyl)prop-2-en-1-one (0.62g, 2.15mmol, 86.0%) (Tables 5, 6 and 7). 
 
Synthesis of (E)-3-(5-bromo-2-hydroxy-3-methoxyphenyl)-1-(3-methoxyphenyl)prop-2-en-1-one 
(2.3c) 
Following the general procedure, aqueous 3M NaOH (10 mL) was added to 
a solution of 5-bromo-2-hydroxy-3-methoxybenzaldehyde (0.51g, 2.2 
ŵŵolͿ aŶd ϯ’-methoxyacetophenone (385µL, 2.119 mmol) in ethanol (10 
mL) leading immediately to a red solution that was stirred for 19 hours at 
room temperature. Then, the reaction mixture was neutralized with 
concentrated HCl forming a yellow suspension that was cooled at 4ºC for 2 hours. After that, the 
yellow solid was filtered and identified by IR, 1H and 13C NMR as (E)-3-(5-bromo-2-hydroxy-3-
methoxyphenyl)-1-(3-methoxyphenyl)prop-2-en-1-one (1.37g, 3.82 mmol, 99.7%) (Tables 5, 6 and 
7). 
 
Synthesis of (E)-3-(5-bromo-2-hydroxyphenyl)-1-(p-tolyl)prop-2-en-1-one (2.3k) 
Following the general procedure, aqueous 3M NaOH (5 mL) was added to a 
solution of 5-bromo-2-hydroxybenzaldehyde (0.34g, 1.71 mmol) and 1-(p-
tolyl)ethanone (320µL, 2.28 mmol) in ethanol (1.6 mL) leading to an orange 
solution that after 2 hours stirring at room temperature turned into dark 
red. After stirring for a total of 19 hours, the solution was neutralized with 
concentrated HCl leading to a yellow suspension kept in the ultrasound bath for a few minutes. A 
yellow solid was filtered, washed with water and ethanol and identified by IR, 1H and 13C NMR as (E)-
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3-(5-bromo-2-hydroxyphenyl)-1-(p-tolyl)prop-2-en-1-one (0.42g, 1.33mmol, 77.8%) (Tables 5, 6 and 
7). 
 
Synthesis of (E)-3-(5-bromo-2-hydroxy-3-methoxyphenyl)-1-(p-tolyl)prop-2-en-1-one (2.3h) 
Following the general procedure, aqueous 3M NaOH (8 mL) was added 
to a solution of 5-bromo-2-hydroxy-3-methoxybenzaldehyde (0.27, 
1.17 mmol) and 1-(p-tolyl)ethanone (171µL, 1.284 mmol) in ethanol (8 
mL) resulting in a red solution. After being stirred for 24 hours at room 
temperature, it was neutralized with concentrated HCl until pH±3 and 
led to a yellow suspension. This suspension was kept in the ultrasound bath for, approximately, half 
an hour, cooled and filtered. The pale yellow isolated product was identified by IR, 1H and 13C NMR 
as (E)-3-(2-hydroxyphenyl)-1-phenylprop-2-en-1-one (0.31g, 0.90mmol, 76.6%) (Tables 5, 6 and 7). 
 
Synthesis of (E)-3-(5-chloro-2-hydroxyphenyl)-1-(p-tolyl)prop-2-en-1-one (2.3g) 
Following the general procedure, aqueous 3M NaOH  (10 mL) was added 
to a solution of 5-chloro-2-hydroxybenzaldehyde (0.38g, 2.44 mmol) and 
1-(p-tolyl)ethanone (358µL, 2.108 mmol) in ethanol (10 mL) leading to a 
red solution. This solution was stirred at room temperature for 18 hours 
and was then it was neutralized with concentrated HCl. A yellow 
suspension was formed and cooled for 1 hour at 4ºC. The yellow product was filtered and identified 
by IR, 1H and 13C NMR as (E)-3-(5-chloro-2-hydroxyphenyl)-1-(p-tolyl)prop-2-en-1-one (0.59g, 2.13 
mmol, 87.3%) (Tables 5, 6 and 7). 
 
Synthesis of (E)-3-(3,5-difluoro-2-hydroxyphenyl)-1-(p-tolyl)prop-2-en-1-one (2.3l) 
Following the general procedure, aqueous 3M NaOH (10 mL) was added 
to a solution of 3,5-difluoro-2-hydroxybenzaldehyde (0.32g, 2.0 mmol) 
and 1-(p-tolyl)ethanone (297µL, 2.2 mmol) in ethanol (10 mL) leading 
immediately to a red solution that was stirred for 5 hours at room 
temperature. Then, the reaction was neutralized at room temperature 
with concentrated HCl forming a pale yellow suspension which was 
cooled for 45 minutes at 4ºC. The light yellow solid was filtered and identified by IR, 1H and 13C NMR 
as (E)-3-(3,5-difluoro-2-hydroxyphenyl)-1-(p-tolyl)prop-2-en-1-one being pure (0.43g, 1.58 mmol, 
78.8%) (Tables 5, 6 and 7). 
 
Synthesis of (E)-3-(5-bromo-2-hydroxyphenyl)-1-(4-bromophenyl)prop-2-en-1-one (2.3i) 
Following the general procedure, aqueous 3M NaOH (12 mL) was added to a 
solution of 5-bromo-2-hydroxybenzaldehyde (0.45g, 2.23 mmol) and 1-(4-
bromophenyl)ethanone (0.49g, 2.46 mmol) in ethanol (12 mL) leading 
immediately to a red precipitate in a red solution. After 6 hours at room 
temperature, the reaction mixture was filtered and a red solid was isolated. 
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A suspension of this solid in 3mL of water was neutralized with concentrated HCl at room 
temperature leading to a yellow solid. The neutralized suspension was cooled at 4ºC for 16 hours. 
Finally, it was isolated a pure yellow product identified by IR, 1H and 13C NMR as (E)-3-(5-bromo-2-
hydroxyphenyl)-1-(4-bromophenyl)prop-2-en-1-one (0.59g, 1.56mmol, 70.0%) (Tables 5, 6 and 7). 
 
 Synthesis of (E)-3-(5-bromo-2-hydroxy-3-methoxyphenyl)-1-(4-bromophenyl)prop-2-en-1-one 
(2.3m) 
Following the general procedure, aqueous 3M NaOH (8 mL) was added 
to a solution of 5-bromo-2-hydroxy-3-methoxybenzaldehyde (0.26g, 
1.14mmol) and 1-(4-bromophenyl)ethanone (0.25g, 1.26mmol) in 
ethanol (8 mL) leading to a red solution stirred at room temperature for 
22 hours. After that, the solution was kept in an ice bath and concentrated HCl was added to pH±2 
turning the red solution into a yellow suspension. The solid was filtered while tepid and the yellow 
product was identified by 1H NMR, the product was identified as (E)-3-(5-bromo-2-hydroxy-3-
methoxyphenyl)-1-(4-bromophenyl)prop-2-en-1-one (0.62g, 1.57mmol, 80.3%) (Table 6). 
 
Synthesis of (E)-3-(3-bromophenyl)-1-(p-tolyl)prop-2-en-1-one (2.3n) 
Following the general procedure, aqueous 3M NaOH (7 mL) was added to a 
solution of 3-bromobenzaldehyde (190µL, 1.62mmol) and 1-(p-
tolyl)ethanone (238µL, 1.78mmol) in ethanol (7 mL) leading immediately to a 
white product in a transparent solution. The reaction mixture was stirred for 
4 hours at room temperature. And the solid was filtered resulting in the 
isolation of a white product from a pale yellow solution. The product was identified by 1H NMR as 
(E)-3-(3-bromophenyl)-1-(p-tolyl)prop-2-en-1-one (0.46g, 1.53mmol, 96.8%) (Tables 5, 6 and 7). 
 
Synthesis of (E)-1-(4-chlorophenyl)-3-(2-hydroxy-5-methylphenyl)prop-2-en-1-one (2.3u) 
Following the general procedure, aqueous 3M NaOH  (5 mL) was added to a 
solution of 2-hydroxy-5-methylbenzaldehyde (0.25g, 1.84mmol) and 1-(4-
chlorophenyl)ethanone (263µL, 2.02mmol) in ethanol (5mL) leading to a red 
solution. The reaction mixture was stirred for 7 hours at room temperature 
and, then, neutralized with concentrated HCl to pH±3 resulting in a yellow 
suspension. As there were some lumps, the suspension was taken to the 
ultrasound bath, for 30 minutes. Finally, the yellow product was filtered and identified by 1H NMR as 
(E)-1-(4-chlorophenyl)-3-(2-hydroxy-5-methylphenyl)prop-2-en-1-one (0.21g, 0.80mmol, 43%), 
contaminated with in a 1:0.25 molar ratio. The contaminated product was suspended in water and 
ethanol (2:1) and the mixture was stirred for 2 hours, the product isolated by filtration maintained 
the impurity. It was attempted a recrystallization of the contaminated solid (0.19g) under 5 minutes 
of reflux in 4mL water and 2mL ethanol (2:1). However, after isolation of a yellow solid (0.17g, 0.56g, 
30.4%) it was observed that the 1-(4-chlorophenyl)ethanone contamination was preserved in a 
similar ratio (Table 6). 
Synthesis of (E)-1-(4-chlorophenyl)-3-(3,5-difluoro-2-hydroxyphenyl)prop-2-en-1-one (2.3s) 
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Following the general procedure, aqueous 3M NaOH (10mL) was added to a 
solution of 3,5-difluoro-2-hydroxybenzaldehyde (0.46g, 3.47mmol) and 1-(4-
chlorophenyl)ethanone (486µL, 3.82mmol) in ethanol (10mL) and resulted in 
a red solution that was stirred at room temperature for 21 hours. After that, 
addition of concentrated HCl to pH±2.10 and led to a yellow suspension taken 
to the ultrasound bath for 1 hour. Finally, the suspension was filtered and the 
solid product was identified by 1H NMR, mostly, as 1-(4-chlorophenyl)ethanone (0.6481g, 2.2mmol, 
63.4%), with traces of (E)-1-(4-chlorophenyl)-3-(3,5-difluoro-2-hydroxyphenyl)prop-2-en-1-one in a 
4.1:1 molar ratio (Table 6). 
 
Synthesis of (E)-3-(5-chloro-2-hydroxyphenyl)-1-phenylprop-2-en-1-one (2.3t) 
Following the general procedure, aqueous 3M NaOH (10mL) was added to a 
solution of 5-chloro-2-hydroxybenzaldehyde (0.50g, 3.17mmol) and 
acetophenone (407µL, 3.49mmol) in ethanol (10mL), leading immediately to a red 
solution, stirred at room temperature for 24 hours. After that, addition of 
concentrated HCl to pH±2/3 led to a yellow suspension taken to the ultrasound 
bath for 30 minutes. The solid was filtered and identified by 1H NMR as (E)-3-(5-
chloro-2-hydroxyphenyl)-1-phenylprop-2-en-1-one (0.58g, 2.25mmol, 71.0%), with traces of 5-
chloro-2-hydroxybenzaldehyde and contaminant 2.5 (Table 6). 
 
Synthesis of (E)-3-(5-bromo-2-hydroxyphenyl)-1-(4-chlorophenyl)prop-2-en-1-one (2.3v) 
Following the general procedure, aqueous 3M NaOH (10 mL) was added to a 
solution of 5-bromo-2-hydroxybenzaldehyde (0.61g, 3.06mmol) and 1-(4-
chlorophenyl)ethanone (361µL, 2.118mmol) in ethanol (10 mL) leading to a 
red solution stirred at room temperature. After 19 hours, the red solution was 
neutralized with concentrated HCl leading to a yellow suspension, cooled at 
4ºC during 2 hours. The yellow product was isolated by filtration and 
identified by 1H NMR as (E)-3-(5-bromo-2-hydroxyphenyl)-1-(4-chlorophenyl)prop-2-en-1-one 
(0.71g, 2.09mmol, 75.2%) contaminated with 5-bromo-2-hydroxybenzaldehyde in a 1:0.6 molar 
ratio. The contaminated product was recrystallized (0.62g) under 3 minutes of reflux in 4mL water 
and 4mL ethanol (1:1). However, after isolation of a yellow solid (0.60g, 1.77mmol, 57.8%) it was 
observed that the benzaldehyde contamination was preserved in a similar ratio (Table 6). 
 
Synthesis of (E)-3-(5-bromo-2-hydroxyphenyl)-1-(4-fluorophenyl)prop-2-en-1-one (2.3z) 
Following the general procedure, aqueous 3M NaOH (7 mL) was added to a 
solution of 5-bromo-2-hydroxybenzaldehyde (0.42g, 2.09mmol) and 1-(4-
fluorophenyl)ethanone (279µL, 2.29mmol) in ethanol (7 mL) leading 
immediately to a red solution. The reaction mixture was stirred for 50 hours at 
room temperature. After that, the reaction vessel was cooled, in an ice bath, 
and concentrated HCl was added to pH±3 leading to a yellow suspension taken 
to the ultrasound bath for 30 minutes. The reaction mixture was filtered leading to a yellow product, 
identified by 1H NMR as (E)-3-(5-bromo-2-hydroxyphenyl)-1-(4-fluorophenyl)prop-2-en-1-one 
(0.65g, 2.02mmol, 96.7%) contaminated with 5-bromo-2-hydroxybenzaldehyde and a contaminant 
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2.5  in a 1:0.57:0.62 molar ratio. It was attempted a recrystallization of the contaminated solid (0.61g) 
under 3 minutes of reflux in 6mL water and 5mL ethanol. The reaction vessel was cooled at room 
temperature. However, after filtration of the light yellow solid (0.55g, 1.70mmol, 81.3%) it was 
observed that both contaminations were preserved in a very similar ratio (Table 6). 
 
Synthesis of (E)-1-(4-chlorophenyl)-3-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one (2.3y) 
Following the general procedure, aqueous 3M NaOH (10mL) was added 
to a solution of 2-hydroxy-4-methoxybenzaldehyde (0.25g, 1.65mmol) 
and 1-(4-chlorophenyl)ethanone (195µL, 1.5mmol) in ethanol (10mL) 
leading immediately to a red solution, stirred at 60ºC for 27 hours. After 
that, concentrated HCl was added to pH±2/3 and the red solution 
turned into a dark orange suspension cooled at 4ºC for 1 hour. The 
suspension was filtered and the solid was identified by 1H NMR as (E)-1-(4-chlorophenyl)-3-(2-
hydroxy-4-methoxyphenyl)prop-2-en-1-one (0.05g, 0.17mmol, 10.4%) (Table 6). 
 
Synthesis of (E)-3-(3,5-difluoro-2-hydroxyphenyl)-1-(3-methoxyphenyl)prop-2-en-1-one (2.3w) 
Following the general procedure, aqueous 3M NaOH (10mL) was added to a 
solution of 3,5-difluoro-2-hydroxybenzaldehyde (0.46g, 2.113mmol) and 1-(3-
methoxyphenyl)ethanone (443µL, 3.23mmol) in ethanol (10mL) leading to a 
red solution, stirred at room temperature for 5 hours. After that, concentrated 
HCl was added to pH±2/3 and the red solution turned into a yellow suspension 
cooled at 4ºC for 1 hour. Finally, the suspension was filtered, and the product 
was identified by 1H NMR as (E)-3-(3,5-difluoro-2-hydroxyphenyl)-1-(3-methoxyphenyl)prop-2-en-1-
one (0.33g, 1.15mmol, 39.2%), contaminated with 1-(3-methoxyphenyl)ethanone in a 1:0.16 molar 
ratio (Table 6). 
 
Synthesis of (E)-1-(4-bromophenyl)-3-(3,5-difluoro-2-hydroxyphenyl)prop-2-en-1-one (2.3x) 
Following the general procedure, aqueous 3M NaOH (8mL) was added to a 
solution of 3,5-difluoro-2-hydroxybenzaldehyde (0.24g, 1.54mmol) and 1-
(4-bromophenyl)ethanone (0.34g, 1.7mmol) in ethanol (8mL) leading 
immediately to a red solution, stirred at room temperature for 22 hours. 
After that, concentrated HCl was added to pH±2 and the red solution turned 
into a yellow suspension, taken to the ultrasound bath for 30 minutes due a solid stuck to the 
magnetic bar. The solid could not be dissociated from the bar so only the suspension was filtered. 
The solid was identified by 1H NMR as 1-(4-bromophenyl)ethanone with traces of (E)-3-(5-chloro-2-
hydroxyphenyl)-1-phenylprop-2-en-1-one (0.2015g, 0.594mmol, 38.6%), in a 1.9:1 molar ratio (Table 
6). 
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1.2. Synthesis of 4H-chromene derivatives 
Synthesis of methyl 2-amino-4-(2-(4-chlorophenyl)-2-oxoethyl)-8-methoxy-4H-chromene-3-
carboxylate (2.10a) 
Triethylamine (150µL) was added to a solution of (E)-1-(4-chlorophenyl)-3-(2-
hydroxy-3-methoxyphenyl)prop-2-en-1-one 2.3y (0.07g; 0.25mmol) and 
methyl 2-cyanoacetate (44µL; 0.5mmol) in methanol (1mL). This orange 
solution was stirred for 7 hours at room temperature and, then, cooled at -
20ºC for 17 hours leading to a beige solid. The solid was filtered, washed with 
ethanol and identified by IR, 1H and 13C NMR as methyl 2-amino-4-(2-(4-
chlorophenyl)-2-oxoethyl)-8-methoxy-4H-chromene-3-carboxylate (0.06g; 
0.18mmol; 71,8%) (Tables 10, 11 and 12). 
 
Synthesis of methyl 2-amino-6-bromo-4-(2-oxo-2-phenylethyl)-4H-chromene-3-carboxylate 
(2.10b) 
Triethylamine (125µL) was added to a solution of (E)-3-(5-bromo-2-
hydroxyphenyl)-1-phenylprop-2-en-1-one 2.3q (0.05g; 0.171mmol) and 
methyl 2-cyanoacetate (38µL; 0.343mmol) in methanol (1mL). This dark 
yellow solution was stirred for 24 hours at room temperature and then 
cooled at -20ºC for 5 hours leading to a white solid. The solid was filtered, 
washed with ethanol and identified by IR, 1H and 13C NMR as methyl 2-
amino-6-bromo-4-(2-oxo-2-phenylethyl)-4H-chromene-3-carboxylate (0.04g; 0.10mmol; 58.5%) 
(Tables 10, 11 and 12). 
 
Synthesis of methyl 2-amino-6-bromo-8-methoxy-4-(2-(3-methoxyphenyl)-2-oxoethyl)-4H-
chromene-3-carboxylate (2.10c) 
Triethylamine (138µL) was added to a solution of (E)-3-(5-bromo-2-
hydroxy-3-methoxyphenyl)-1-(3-methoxyphenyl)prop-2-en-1-one 2.3c 
(0.08g; 0.24mmol) and methyl 2-cyanoacetate (42µL; 0.48mmol) in 
methanol (1mL). This light yellow solution was stirred for 17 hours, at room 
temperature, and cooled at -20ºC for 23 hours. As there was no 
precipitation, 2 mL of water were added leading to a gummy substance that 
clung to the magnetic bar. The use of the ultrasound bath to break up the 
solid was inconsequent. So, we proceed to the addition of 2mL of ethanol and, again, took the 
solution to the ultrasound bath for 1 hour. A white solid precipitated and was filtered. The solid was 
identified by IR, 1H and 13C NMR as methyl 2-amino-6-bromo-8-methoxy-4-(2-(3-methoxyphenyl)-2-
oxoethyl)-4H-chromene-3-carboxylate (0.07g,0.15mmol, 62.10%) (Tables 10, 11 and 12). 
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Synthesis of methyl 2-amino-6-bromo-4-(2-(4-chlorophenyl)-2-oxoethyl)-4H-chromene-3-
carboxylate (2.10d) 
Triethylamine (66µL) was added to a solution of (E)-3-(5-bromo-2-
hydroxyphenyl)-1-(4-chlorophenyl)prop-2-en-1-one 2.3v (0.07g; 
0.21mmol) and methyl 2-cyanoacetate (20µL; 0.23mmol) in methanol 
(1mL). This yellow solution was stirred for 4 hours at room temperature. 
The solid was filtered, washed with ethanol and identified by IR, 1H and 13C 
NMR as methyl 2-amino-6-bromo-4-(2-(4-chlorophenyl)-2-oxoethyl)-4H-
chromene-3-carboxylate (0.05g, 0.12mmol, 57.1%) (Tables 10, 11 and 12). 
 
Synthesis of methyl 2-amino-6-bromo-4-(2-(4-chlorophenyl)-2-oxoethyl)-8-methoxy-4H-
chromene-3-carboxylate (2.10e) 
Triethylamine (95µL) was added to a solution of (E)-3-(5-bromo-2-
hydroxyphenyl)-1-phenylprop-2-en-1-one 2.3q (0.11g; 0.3mmol) and 
methyl 2-cyanoacetate (29µL; 0.33mmol) in methanol (1mL). The mixture 
was stirred for 21 hours, at room temperature and then cooled at -20ºC 
during 3 hour, leading to a light pink solid. The solid was filtered and 
identified by IR, 1H and 13C NMR as methyl 2-amino-6-bromo-4-(2-(4-
chlorophenyl)-2-oxoethyl)-8-methoxy-4H-chromene-3-carboxylate (0.09g; 
0.21mmol; 69.3%) (Tables 10, 11 and 12). 
 
Synthesis of methyl 2-amino-6-chloro-4-(2-oxo-2-phenylethyl)-4H-chromene-3-carboxylate 
(2.10f) 
Triethylamine (138µL) was added to a solution of (E)-3-(5-bromo-2-
hydroxy-3-methoxyphenyl)-1-(3-methoxyphenyl)prop-2-en-1-one 2.3t 
(0.08g; 0.24mmol) and methyl 2-cyanoacetate (42µL; 0.48mmol) in 
methanol (1mL). This light yellow solution was stirred for 17 hours, at room 
temperature, and cooled at -20ºC for 23 hours. As there was no 
precipitation, 2 mL of water were added leading to a gummy substance that 
clung to the magnetic bar. The use of the ultrasound bath to break up the 
solid was inconsequent. So, we proceed to the addition of 2mL of ethanol and, again, took the 
solution to the ultrasound bath for 1 hour. A white solid precipitated and was filtered. The solid was 
identified by IR, 1H and 13C NMR as methyl 2-amino-6-bromo-8-methoxy-4-(2-(3-methoxyphenyl)-2-
oxoethyl)-4H-chromene-3-carboxylate (0.05g, 0.14mmol, 56.5%) (Tables 10, 11 and 12). 
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Synthesis of methyl 2-amino-6-bromo-4-(2-(4-bromophenyl)-2-oxoethyl)-4H-chromene-3-
carboxylate (2.10g) 
Triethylamine (95µL) was added to a solution of (E)-3-(5-bromo-2-
hydroxyphenyl)-1-(4-bromophenyl)prop-2-en-1-one 2.3i (0.04g; 0.11mmol) 
and methyl 2-cyanoacetate (20µL; 0.22mmol) in methanol (1mL). The 
mixture was stirred for 18 hours, at room temperature and then cooled at -
20ºC during 6 hours, leading to a white solid. The solid was filtered and 
identified by IR, 1H and 13C NMR as methyl 2-amino-6-bromo-4-(2-(4-
bromophenyl)-2-oxoethyl)-4H-chromene-3-carboxylate (0.04g; 0.10mmol; 94.5%) (Tables 10, 11 and 
12). 
 
Synthesis of methyl 2-amino-6-bromo-4-(2-(4-bromophenyl)-2-oxoethyl)-8-methoxy-4H-
chromene-3-carboxylate (2.10h) 
Triethylamine (66µL) was added to a solution of (E)-3-(5-bromo-2-hydroxy-
3-methoxyphenyl)-1-(4-bromophenyl)prop-2-en-1-one 2.3m (0.05g; 
0.14mmol) and methyl 2-cyanoacetate (24µL; 0.27mmol) in methanol 
(1.2mL). This yellow solution was stirred for 5 hours at room temperature. 
A with solid was filtered and identified by IR, 1H and 13C NMR as methyl 2-
amino-6-bromo-4-(2-(4-bromophenyl)-2-oxoethyl)-8-methoxy-4H-
chromene-3-carboxylate (0.0524g, 0.12mmol, 57.1%) (Tables 10, 11 and 
12). 
 
Synthesis of 2-amino-4-(2-oxo-2-phenylethyl)-4H-chromene-3-carbonitrile (2.11a) 
Triethylamine (99µL) was added to a solution of (E)-3-(2-hydroxyphenyl)-1-
phenylprop-2-en-1-one 2.3o (0.05g; 0.19mmol) with malononitrile (0.03g; 
0.47mmol) in ethanol (1.2mL). The mixture was stirred for 4 hours, at room 
temperature and then cooled to -20ºC for 17 hours, leading to a white solid. The 
solid was filtered and identified by IR, 1H and 13C NMR as 2-amino-4-(2-oxo-2-
phenylethyl)-4H-chromene-3-carbonitrile (0.02g; 0.06mmol; 27.0%) (Tables 10, 13 
and 14). 
 
Synthesis of 2-amino-6-bromo-4-(2-oxo-2-(p-tolyl)ethyl)-4H-chromene-3-carbonitrile (2.11b) 
Triethylamine (80µL) was added to a solution of (E)-3-(5-bromo-2-
hydroxyphenyl)-1-(p-tolyl)prop-2-en-1-one 2.3k (0.05g; 0.19mmol) and 
malononitrile (0.02g; 0.37mmol) in ethanol (1.5mL). The mixture was stirred for 
6 hours at room temperature and then cooled at -20ºC for 19 hours, leading to 
white crystals. The crystals were filtered and identified by IR, 1H and 13C NMR 
as 2-amino-6-bromo-4-(2-oxo-2-(p-tolyl)ethyl)-4H-chromene-3-carbonitrile 
(0.04g; 0.12mmol; 61.8%) (Tables 10, 13 and 14). 
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Synthesis of 2-amino-6-bromo-8-methoxy-4-(2-oxo-2-phenylethyl)-4H-chromene-3-carbonitrile 
(2.11c) 
Triethylamine (67µL) was added to a solution of (E)-3-(5-bromo-2-hydroxy-3-
methoxyphenyl)-1-phenylprop-2-en-1-one 2.3a (0.05g; 0.15mmol) and 
malononitrile (0.02g; 0.31mmol) in ethanol (1.5mL) leading to a light orange 
solution. The solution was stirred for 5 hours, at room temperature, and 
cooled to -20ºC for 1 hour, leading to a white solid precipitate in an orange 
solution. The solid was filtered and identified by IR, 1H and 13C NMR as 2-
amino-6-bromo-8-methoxy-4-(2-oxo-2-phenylethyl)-4H-chromene-3-
carbonitrile (0.03g; 0.06mmol; 41.8%) (Tables 10, 13 and 14). 
 
Synthesis of 2-amino-6-bromo-4-(2-(4-chlorophenyl)-2-oxoethyl)-8-methoxy-4H-chromene-3-
carbonitrile (2.11d) 
Triethylamine (58µL) was added to a solution of (E)-3-(5-bromo-2-hydroxy-3-
methoxyphenyl)-1-(4-chlorophenyl)prop-2-en-1-one 2.3b (0.05g; 0.14mmol) 
and malononitrile (0.02g; 0.27mmol) in ethanol (1.5mL) leading to a light 
orange solution. The solution stirred for 5 hours, at room temperature and then 
cooled to -20ºC for 17 hours, leading to the precipitation a white solid in an 
orange solution. The solid was filtered and identified by IR, 1H and 13C NMR as 
2-amino-6-bromo-4-(2-(4-chlorophenyl)-2-oxoethyl)-8-methoxy-4H-chromene-3-carbonitrile 
(0.04g; 0.10mmol; 68.1%) (Tables 10, 13 and 14). 
 
Synthesis of 2-amino-6-bromo-8-methoxy-4-(2-(3-methoxyphenyl)-2-oxoethyl)-4H-chromene-3-
carbonitrile (2.11e) 
Triethylamine (69µL) was added to a solution of (E)-3-(5-bromo-2-hydroxy-3-
methoxyphenyl)-1-(3-methoxyphenyl)prop-2-en-1-one 2.3c (0.06g; 0.16mmol) 
and malononitrile (0.02g; 0.32mmol) in ethanol (1mL)  resulting in a dark yellow 
solution. The solution was stirred for 7 hours, at room temperature, and cooled 
to -20ºC for 17 hours, leading to a white solid precipitate in an orange solution. 
The solid was filtered, washed with ethanol and the white product was 
identified by IR, 1H and 13C NMR as 2-amino-6-bromo-8-methoxy-4-(2-(3-
methoxyphenyl)-2-oxoethyl)-4H-chromene-3-carbonitrile (0.04g; 0.10mmol; 63.8%) (Tables 10, 13 
and 14). 
 
Synthesis of 2-amino-6-chloro-4-(2-oxo-2-(p-tolyl)ethyl)-4H-chromene-3-carbonitrile (2.11f) 
Triethylamine (87µL) was added to a solution of (E)-3-(5-chloro-2-
hydroxyphenyl)-1-(p-tolyl)prop-2-en-1-one 2.3g (0.06g; 0.20mmol) and 
malononitrile (0.03g; 0.40mmol) in ethanol (1.5mL)  resulting in a yellow 
solution. The solution was stirred for 5 hours, at room temperature, leading to 
a beige suspension. The product was filtered and the white solid identified by 
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IR, 1H and 13C NMR as 2-amino-6-chloro-4-(2-oxo-2-(p-tolyl)ethyl)-4H-chromene-3-carbonitrile 
(0.03g; 0.08mmol; 39.6%) (Tables 10, 13 and 14). 
 
Synthesis of 2-amino-6-bromo-4-(2-(3-methoxyphenyl)-2-oxoethyl)-4H-chromene-3-carbonitrile 
(2.11g) 
Triethylamine (94µL) was added to a solution of (E)-3-(5-bromo-2-
hydroxyphenyl)-1-(3-methoxyphenyl)prop-2-en-1-one 2.3e (0.07g; 0.22mmol) 
and malononitrile (0.03g; 0.44mmol) in ethanol (2mL)  resulting in a yellow 
solution. The solution was stirred for 4 hours, at room temperature and cooled 
to -20ºC for 18 hours leading to an orange solution with a white solid 
precipitate. The solid was filtered, briefly washed with ethanol and identified 
by IR, 1H and 13C NMR as being 2-amino-6-bromo-4-(2-(3-methoxyphenyl)-2-
oxoethyl)-4H-chromene-3-carbonitrile (0.02g; 0.05mmol; 24.7%) (Tables 10, 13 and 14). 
 
Synthesis of 2-amino-6,8-difluoro-4-(2-oxo-2-phenylethyl)-4H-chromene-3-carbonitrile (2.11h) 
Triethylamine (99µL) was added to a solution of (E)-3-(3,5-difluoro-2-
hydroxyphenyl)-1-phenylprop-2-en-1-one 2.3f (0.06g; 0.23mmol) and 
malononitrile (0.03g; 0.46mmol) in ethanol (2mL) leading to a yellow solution. 
The solution was stirred for 17 hours, at room temperature and cooled to -20ºC 
for 3 hours leading to a light yellow solution with white solid precipitate. The 
white product was filtered and identified by IR, 1H and 13C NMR as 2-amino-6,8-
difluoro-4-(2-oxo-2-phenylethyl)-4H-chromene-3-carbonitrile (0.02g; 
0.05mmol; 21.4%) (Tables 10, 13 and 14). 
 
Synthesis of 2-amino-6-bromo-8-methoxy-4-(2-oxo-2-(p-tolyl)ethyl)-4H-chromene-3-carbonitrile 
(2.11i) 
Triethylamine (71µL) was added to a solution of (E)-3-(5-bromo-2-hydroxy-3-
methoxyphenyl)-1-(p-tolyl)prop-2-en-1-one 2.3h (0.06g; 0.17mmol) and 
malononitrile (0.02g; 0.33mmol) in ethanol (2mL)  leading to an orange 
solution. The solution was stirred at room temperature for 23 hours and cooled 
to -20ºC for 7 days leading to a light yellow solution with white solid precipitate. 
The white product was filtered and identified by IR, 1H and 13C NMR as 2-amino-
6-bromo-8-methoxy-4-(2-oxo-2-(p-tolyl)ethyl)-4H-chromene-3-carbonitrile 
(0.01g, 0.02mmol, 12.1%) (Tables 10, 13 and 14). 
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Synthesis of 2-amino-6-bromo-4-(2-(4-bromophenyl)-2-oxoethyl)-4H-chromene-3-carbonitrile 
(2.11j) 
Triethylamine (48µL) was added to a solution of (E)-3-(5-bromo-2-
hydroxyphenyl)-1-(4-bromophenyl)prop-2-en-1-one 2.3i (0.04g; 0.11mmol) 
and malononitrile (0.02g; 0.23mmol) in ethanol (2mL) leading to a light orange 
solution. The solution was stirred for 2 hours, at room temperature and then 
cooled at -20ºC for 38 hours leading to a white solid precipitate in an orange 
solution. The white product was filtered and identified by IR, 1H and 13C NMR 
as 2-amino-6-bromo-4-(2-(4-bromophenyl)-2-oxoethyl)-4H-chromene-3-
carbonitrile (0.03g; 0.06mmol; 50.3%) (Tables 10, 13 and 14). 
 
Synthesis of 2-amino-6-bromo-4-(2-(4-bromophenyl)-2-oxoethyl)-8-methoxy-4H-chromene-3-
carbonitrile (2.11k) 
Triethylamine (65µL) was added to a solution of (E)-3-(5-bromo-2-hydroxy-3-
methoxyphenyl)-1-(4-bromophenyl)prop-2-en-1-one 2.3m (0.06g; 0.15mmol) 
and malononitrile (0.03g; 0.30mmol) in ethanol (1.2mL)  leading to a light 
orange solution. The solution was stirred for 5 hours at room temperature and 
cooled at -20ºC for 14 hours. After 4 more hours at room temperature, a white 
solid precipitated in a dark yellow solution. The white product was filtered and 
identified by IR, 1H and 13C NMR as 2-amino-6-bromo-4-(2-(4-bromophenyl)-2-
oxoethyl)-8-methoxy-4H-chromene-3-carbonitrile (0.04g; 0.09mmol; 56.6%) 
(Tables 10, 13 and 14). 
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2. BiologiĐal assaǇs  
2.1. Cell lines and culture conditions  
 
Two human breast cancer cell lines Hs578T (basal subtype) and MCF-7 (luminal subtype), and a 
normal breast cell line MCF-10A, were obtained from ATCC (American Type Culture Collection). 
The two cancer cell liŶes ǁeƌe Đultuƌed iŶ DulďeĐĐo’s modified Eagle medium, 4.5g/l glucose 
(DMEM, Gibco) supplemented with 10% heating activated Fetal Bovine Serum (FBS, Gibco) and 
1% antibiotic solution (Penicillin-Streptomycin, Gibco). The normal cell line was cultured in 
Dulbecco's Modified Eagle Medium:Nutrient Mixture F-12 (DMEM/F12, Gibco) supplemented 
with 5% heating activated Fetal Bovine Serum (FBS, Gibco), 1% antibiotic solution (Penicillin-
Streptomycin, Gibco), 1% steroid hormone (Hydrocortisone, Sigma-Aldrich), 0.1% peptide 
hormone (Insulin, Sigma-Aldrich) and 0.01% protein complex (Cholera Toxin, Gibco). Cells were 
grown in a humidified incubator at 37C and 5% CO2. For all assays, DMSO (Dimethyl Sulfoxide, 
Sigma-Aldrich) controls were used. 
To cultivate cells for any assay, sub-confluent cells were reaped by gently washing flasks with 
phosphate-buffer saline (PBS 1x) and then detaching with trypsin (TƌǇpLE™ Eǆpƌess, Gibco) at 
37C. To inactivate trypsin DMEM 10% FBS or DMEM/F12 5% FBS were added and cells were 
collected and centrifuged 5 minutes at 900rpm. Cells were suspended in new medium and 10µl 
of cell suspension were collected, in which 20µl of trypan blue (Trypan Blue Solution, 0.4%, 
Gibco) was added. Cells were counted in a Neubauer chamber for posterior density calculation. 
 
2.2. Cell viability assays 
2.2.1. Sulforhodamine B assay 
Sulforhodamine B assay is based on the quantification of protein from viable cells, allowing cell 
biomass determination. This method is mainly used to toxicity screening of drugs and 
chemosensitivity. In this approach, protein basic amino acid residues are electrostatically bound 
to sulforhodamine B, a protein dye. 
For the first screen and to determine the compounds IC50 value for the different breast cancer 
cell lines, cells were plated in 96-well plates, at a 3000 cells/100µL density per well for all the 
cell lines (HS578t, MCF-7 and MCF-10). Cells were allowed to adhere for 18 to 20 hours 
(overnight) and then were exposed to various compound concentrations used for a total of 72 
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hours treatment. Controls were performed with 0.3% of DMSO (compound vehicle). The 
compound cytotoxic effect was evaluated by the Sulforhodamine B assay (SRB, TOX-6, Sigma-
Aldrich). After cell incubation with the different compound concentrations, culture medium was 
removed and cells were fixed with cold 10% Trichloroacetic Acid (TCA) for 1h at 4ºC. Plates were 
rinsed 3 times with distilled water to eliminate TCA excess and then were dried overnight at 
room temperature. Cells were stained with 0.4% Sulforhodamine B solution during 30 minutes 
and, after the dying period, plates were again rinsed 3 times with 1% acetic acid until the 
unincorporated dye was totally removed. Then, plates were dried overnight and after this time, 
the incorporated Sulforhodamine B was solubilized in a 10mM Tris Base Solution, stirring in the 
plate shaker for 20 to 30 minutes at room temperature until a homogenous color is obtained. 
Spectrophotometric measurement of absorbance was read at 490nm, using 690nm as 
background absorbance (Tecan Infinite M200). GraphPad Prism 5 software was used for the 
analysis and IC50 values from three independent experiments (at least), each one in triplicate, 
applying a sigmoidal dose-response (variable slope) non-linear regression, after logarithmic 
transformation.  
 
2.2.2. Trypan blue assay 
Trypan blue assay is a dye exclusion test that allows the determination of number of viable cells. 
As live cells possess undamaged cell membranes, they will exclude certain dyes, such as trypan 
blue, leading to a clear cytoplasm. On the other hand, dead cells will be susceptible to the 
colorant, presenting a blue cytoplasm. 
MCF-10 and MCF-7 cells were plated in 12-well plates at a density of 30000 and 50000 cells, 
respectively, per 1mL, and grown overnight at 37°C in a 5% CO2 humidified atmosphere. 
Adherent cells were treated with compounds 2.3e, 2.3g, 2.3i and 2.11e at IC50, ½ IC50 and ¼ IC50 
concentrations or 0.5% DMSO (controls). At 24, 48 and 72 hours, cells were reaped by gently 
rinsing flasks with 200µL of phosphate-buffer saline (PBS 1x) and then detaching with 100 µL 
trypsin at 37C. To inactivate trypsin, 200 µL DMEM/F12 5% FBS or DMEM 10% FBS were added 
and 20µl of cell suspension were collected, in which 20µl of trypan blue (1:1) was added. Cells 
were counted in a Neubauer chamber for posterior density calculation. For each well, a duplicate 
count was made. The analysis and IC50 values were estimated from three independent 
experiments (at least), each one in duplicate, using the GraphPad Prism 5 software, applying a 
sigmoidal dose-response (variable slope) non-linear regression, after logarithmic 
transformation.  
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2.3. Proliferation assay 
DNA synthesis of cells was measured by BrdU assay (Roche Applied Sciences). BrdU cell 
proliferation assay is a colorimetric immunoassay based on the quantification of 5-bromo 2´-
deoxyuridine (BrdU) incorporation in cells, a pyrimidine analog, during DNA synthesis. 
MCF-10 and MCF-7 cells were plated in 96-well plates at a density of 8000cells/100µl, and grown 
overnight at 37°C in a 5% CO2 humidified atmosphere. Then, adherent cells were treated with 
compounds 2.3e, 2.3g, 2.3i and 2.11e at IC50 and ½ IC50 concentrations or 0.5% DMSO (controls) 
for 24 and 48 hours. After incubation, cells were labeled by addition of 5µl/well BrdU labeling 
solution (final concentration: 20 µM BrdU) reincubating for 6 hours to allow BrdU to incorporate 
into the proliferating cell DNA, replacing thymidine. After labeling, culture medium was 
removed, cells were fixed and DNA was denatured through incubation with 100µl of FixDenat 
solution at room temperature. Denaturation of DNA is essential for antibody conjugate binding 
to the incorporated BrdU. After 30 minutes, FixDenat solution was removed, and 50µl of Anti-
BrdU-POD antibody was incubated for 90 minutes at room temperature. The Anti-BrdU-POD 
antibody binds to the incorporated BrdU in the newly synthesized cellular DNA. The antibody 
conjugate was removed and wells were washed three times with PBS 1X. The immune 
complexes were detected by the addition of Substrate solution (100µl/well) and the plate was 
incubated at room temperature until color development was satisfactory for photometric 
detection (5-10 minutes). Substrate reaction was stopped by adding 25µl of 1M H2SO4 to each 
well and softly mixed. The reaction product was quantified by measuring absorbance at 450nm 
(reference wavelength: 690nm) in a microplate reader (Tecan Infinite M200). A blank test was 
used in each experimental time point, without cells, performing all steps described above. The 
results of at least three independent experiments (in triplicate) were evaluated with GraphPad 
Prism 5 software. 
 
2.4. Migration assay 
Cell migration was assessed by the wound-healing assay that allows to mimic the cell migration 
during wound-healing in vivo. This method is based in making a scratch, simulating a wound in 
a cell monolayer, capturing the images at the beginning and regular intervals during cell 
migration to close the wound and comparing the images to quantify the cell migration rate. 
MCF-7 were plated in 6-well plates at a density of 9.0x105/2ml and grown overnight at 37C in 
a 5% CO2 humidified atmosphere. Two scratches were made with a 200µl pipette tip in confluent 
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cells. Cells were gently washed with 500µL 1x PBS and were treated with compounds 2.3e, 2.3g, 
2.3i and 2.11e at the respective IC50, ½ IC50 or 0.5% DMSO (control), for 72 hours. At 0, 12, 24, 
48 and 72 hours specific wound sites (four positions for each wound) were photographed at 
100x magnification using an Olympus IX51 inverted microscope equipped with an Olympus DP20 
Digital Camera System. Assessment of five migration distances were performed with the 
MeVisLab platform and the percentage of cell migration normalized to the control was 
evaluated with the GraphPad Prism 5 software. Three independent experiments were 
performed for each compound. 
 
2.5. Protein extraction and Western Blot 
Protein expression levels were determined by Western blot analysis, a technique that involves 
the transference of proteins that have been separated by gel electrophoresis onto a membrane, 
followed by immunological detection. In this assay cleaved caspase-3 and PARP (Poly (ADP-
ribose) polymerase) were analyzed to confirm the type of cell death, in which caspase-3 is one 
of the key proteins involved in apoptosis, responsible for proteolytic cleavage of nuclear protein 
PARP. 
Cells (MCF-10 and MCF-7) were grown in T25 flasks and, at 70-80% confluence, cells were 
treated with compounds 2.3e, 2.3g, 2.3i and 2.11e at the respective IC50 or 0.5% DMSO 
(controls) for 24 hours. After treatment, cells were collected by scraping and centrifuged at 
2000rpm for 5 minutes at room temperature. The supernatant was discarded and the pellet was 
suspended in lysis buffer (50mM Tris pH 7.6-8, 150mM NaCl, 5mM EDTA, 1mM Na3VO4, 10mM 
NaF, 1% NP-40, 1 % Triton-X100 and 1/7 protease inhibitor cocktail (Roche Applied Sciences)) 
and incubated for 15 minutes on ice. Lysates were centrifuged at 13000 rpm for 15 minutes at 
4C and the supernatants collected for protein concentration determination using the DC 
Protein Assay Kit (BioRad).  
Twenty µg of total protein of each sample were separated on 10-12% polyacrylamide gel (90V 
for 30 minutes and more 120V for 90 minutes) and transferred to a nitrocellulose membrane 
(100V for 60 minutes). Membranes were blocked with 5% milk in 1X TBS for 60 minutes before 
overnight incubation with the specific primary antibodies at 4C (rabbit anti-CAIX antibody, 
1:2000 5% milk, Cell Signaling (#5648); rabbit anti-PARP antibody, 1:1000 5% BSA, Cell Signaling 
(#5625); rabbit anti-caspase-9 antibody, 1:1000 5% BSA, Cell Signaling (#9502); goat anti-Tubulin 
antibody, 1:50000 5% BSA, Santa Cruz Biotechnology (sc-1616)). After washing 5 minutes (2 
times) and more 15 minutes (1 time) with 0.1% Tween 20, blots were incubated for 1 hour with 
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the respective secondary antibodies at room temperature (anti-rabbit IgG-HRP (sc-2034) and 
anti-goat IgG-HRP (sc-2020) secondary antibodies, 1:5000 5% milk, Santa Cruz Biotechnology). 
After washing 5 minutes (twice) and further 15 minutes (once) with TBS/0.1% Tween 20, 
immunoreactive bands were detected with chemiluminescent SuperSignal West Femto Kit 
(Pierce, Thermo Scientific) on ChemiDoc XRS+system (BioRad). The results of two independent 
protein extractions were quantified using the ImageJ software: the density of each band was 
measured and the correspondent value was divided by the Actin (loading control) value. 
Calculation of cleaved protein was performed as follows: Cleaved band/ (Total band + Cleaved 
band). 
 
2.6. Statistical analysis 
All graphs and statistical analysis were performed with the GraphPad Prism 6 software. 
Statistical significance was assessed by the t-test and results are presented as normalized means 
± SD. 
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